GENOMICS STUDY OF ANTI-TUBERCULOSIS
DRUG-INDUCED HYPERSENSITIVITY REACTIONS

Dr Khadija Ahmed Shebe
Student number: SHBKHA004

Thesis submitted to the University of Cape Town
In partial fulfilment of the requirement for the degree

Master of Medicine (MMed) in Dermatology

Faculty of Health Sciences
UNIVERSITY OF CAPE TOWN

12th May, 2015

Supervisor:
Dr Rannakoe Lehloenya
Supernumerary Consultant and Part-time Lecturer
Division of Dermatology
Faculty of Health Sciences, University of Cape Town

Co-Supervisor:
Professor Gail Todd
Emeritus professor
Division of Medicine
Faculty of Health Sciences, University of Cape Town
The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non-commercial research purposes only.

Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author.
Declaration

I, Dr Khadija Ahmed Shebe hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university.

I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever.

Signature:  

Signed by candidate  
Signature removed

Date: 12th May, 2015
Dedication

I would like to express my sincere gratitude to Allah for making it possible for me to accomplish my goals. Exceptional thanks to my wonderful, understanding, loving husband Dr Hussein Mwanga and our beautiful twins Adeel and Adeelah, I love you very much.

Special thanks to my parents (Mr. Ahmed Shebe and Mrs. Nafisa Shebe); my sisters and brothers for their encouragement, love and support throughout my training.
Acknowledgements

I would like to express my sincere gratitude to my supervisor Dr Rannakoe J Lehloeny and my co-supervisor Professor Gail Todd for their infinite guidance, support, diligence and tolerance throughout this project.

I would like to express my appreciation to our collaborators in Taiwan, Galderma John Moche Award and Dermatological Society of South Africa for funding part of my research.

I would like to express my sincere thanks to Wen-Hung Chung and Shuen-Iu Hung for their inputs, assistance and being part of the research since day one.

I am most grateful to Rudzani Muloiwa for his inputs on data analysis and a helping hand throughout the project.

I wish to thank the following for their encouragement and assistance throughout the research project:
Juliet Esterhuizen
Vivian Woodburne
Dermatology department team at Groote Schuur Hospital
Abstract

Introduction: All first-line anti-tuberculosis drugs can be associated with all phenotypes of cutaneous adverse drug reactions (CADR). Second-line drugs are associated with much poorer outcomes. Thus, identifying the offending drug in poly-pharmacy is difficult. Re-challenge with the drug is the gold standard in identifying the offender, however poses unacceptably high risk of CADR recurrence. Population and drug-specific genomics help identify those susceptible to adverse reactions to a drug facilitating avoidance of the drug.

Objective: To investigate the genomic susceptibility in patients with confirmed rifampicin and or isoniazid-associated hypersensitivity reactions using both genome-wide association studies and candidate gene approaches.

Methods: A case control study using 14 patients with previous tuberculosis-associated CADR who were re-challenged with first-line anti-tuberculosis drugs and subsequently developed re-challenge reactions to either isoniazid or rifampicin as cases. These were compared with 30 controls who had tolerated rifampicin and isoniazid during the re-challenge process (12 patients, Group 1a) and consecutive patients who had been on TB treatment for at least 12 weeks without developing any adverse drug reaction (18 patients, Group 1b) and 200 black South Africans from the general population. HLA genotypes of the samples were determined by SeCore® HLA Sequence based typing (Invitrogen, Life technologies, USA), and potential ambiguities were resolved by sequencing-based typing.

Results: We found HLA-B*58:02 (OR=3.6; 95% CI: 1.4-8.99) and HLA-DRB1*09:01 (OR=15.3; 95% CI: 2.1-113.1) to be significantly more prevalent in patients who developed rifampicin and isoniazid-associated CADR as compared to black South African general population. However, we found no significant associations between HLA genotype and rifampicin/isoniazid-associated CADR when we compared the cases to our study controls that had tolerated rifampicin and isoniazid. HLA-B *58.02 was not
found to be statistically associated with HIV positive status (p=0.42) and DRESS phenotype (p=0.6279). The majority of our cases were black Africans. Approximately 80% of our cases and controls were HIV-infected. DRESS/DIHS was the prevalent phenotype of CADR, accounting for approximately 80% of cases and controls.

**Discussion:** To our knowledge, this is the first study to show an association between HLA-B*58:02 and HLA-DRB1*09:01 alleles and severe cutaneous adverse drugs reactions secondary to rifampicin and isoniazid in an African population. We identify 2 candidate HLA alleles that need confirmation of their association in African patients who develop rifampicin or isoniazid-associated CADR in larger studies. The value of identifying candidate alleles could lead to CADR preventative screening prior to initiating anti-tuberculosis therapy in black South Africans. The HLA-B*58:02 noted in our cases and controls tolerant of the drugs might not be associated with CADR but could be a reflection of the HIV status and control in HIV-TB co-infected persons.

**Conclusion:** HLA-B*58:02 and HLA-DRB1*09:01 may be associated with rifampicin and isoniazid-associated CADR. Alternately HLA-B*58:02 may be associated with HIV status rather than CADR. A sufficiently powered study is needed to confirm this association.
## Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title page</td>
<td>1</td>
</tr>
<tr>
<td>Declaration</td>
<td>2</td>
</tr>
<tr>
<td>Dedication</td>
<td>3</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>4</td>
</tr>
<tr>
<td>Abstract</td>
<td>5</td>
</tr>
<tr>
<td>Table of contents</td>
<td>7</td>
</tr>
<tr>
<td>List of tables</td>
<td>8</td>
</tr>
<tr>
<td>List of figures</td>
<td>9</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>10</td>
</tr>
<tr>
<td>CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW</td>
<td>11</td>
</tr>
<tr>
<td>1. Literature review and background to the study</td>
<td>12</td>
</tr>
<tr>
<td>1.1. Tuberculosis</td>
<td>12</td>
</tr>
<tr>
<td>1.2. Adverse drug reactions</td>
<td>14</td>
</tr>
<tr>
<td>1.3. Cutaneous adverse drug reactions</td>
<td>15</td>
</tr>
<tr>
<td>2. Pathogenesis</td>
<td>22</td>
</tr>
<tr>
<td>2.1. Adverse drug reaction pathogenesis</td>
<td>22</td>
</tr>
<tr>
<td>2.2. Tuberculosis adverse drug reaction pathogenesis</td>
<td>25</td>
</tr>
<tr>
<td>3. Tuberculosis management</td>
<td>27</td>
</tr>
<tr>
<td>4. Drug causality and re-challenge</td>
<td>28</td>
</tr>
<tr>
<td>5. Summary</td>
<td>31</td>
</tr>
<tr>
<td>6. References</td>
<td>32</td>
</tr>
<tr>
<td>CHAPTER 2: PUBLICATION-READY MANUSCRIPT</td>
<td>37</td>
</tr>
<tr>
<td>Title page</td>
<td>38</td>
</tr>
<tr>
<td>Abstract</td>
<td>39</td>
</tr>
<tr>
<td>1. Introduction</td>
<td>40</td>
</tr>
<tr>
<td>2. Results</td>
<td>42</td>
</tr>
</tbody>
</table>
3. Discussion ........................................................................................................................................45
4. Materials and Methods ...................................................................................................................48
5. Conflicts of interest & Acknowledgements ............................................................................53
6. References .....................................................................................................................................54
7. Tables .............................................................................................................................................57
8. Figures ............................................................................................................................................63
9. Supplementary materials .............................................................................................................64

List of tables

CHAPTER TWO: PUBLICATION-READY MANUSCRIPT

Table 1: Demographic and clinical characteristics of 14 cases that developed a re-challenge reaction to rifampicin and/or isoniazid and 30 controls who tolerated rifampicin and/or isoniazid .........................................................................................................................57
Table 2: The association between HLA- genotype and the HIV status .........................................58
Table 3: Comparison of the HLA-B allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and the two control groups ...............59
Table 4: Comparison of the HLA-DRB1 allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and black South African from the general population ..................................................................................................................60
Table 5: Comparison of the HLA-C allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and black South African from the general population ..................................................................................................................61
Table 6: Comparison of the HLA-A allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and black South African from the general population ..................................................................................................................62
List of Figures

CHAPTER 1:

Figure 1: Morbilliform rash .......................................................... 16
Figure 2: Urticaria ........................................................................... 17
Figure 3: Angioedema .................................................................... 17
Figure 4: Photosensitivity drug reaction ........................................ 18
Figure 5: Lichenoid drug eruption .................................................. 19
Figure 6: Fixed drug eruption ......................................................... 19
Figure 7: Generalised bullous fixed drug reaction ........................ 19
Figure 8: Steven’s Johnson syndrome .......................................... 21
Figure 9: Toxic epidermal necrolysis ............................................. 21
Figure 10: Drug reaction with eosinophilia and systemic symptoms .................................................................................. 22

CHAPTER 2:

Figure 1: Summary of cases and two control groups of the study ................................................. 63

CHAPTER 3: APPENDICES ................................................................. 69

Appendix 1a: Letter of Approval from Human Research Ethics Committee .................. 70
Appendix 1b: Human Research Ethics Committee Annual Progress Report .......... 71
Appendix 2a: English Consent Form ........................................................................ 72
Appendix 2b: Xhosa Consent Form ........................................................................ 74
Appendix 2c: Afrikaans Consent Form ..................................................................... 76
Appendix 3: Clinical research form ........................................................................ 78
Appendix 4: Journal of investigative dermatology instructions to authors .......... 86
Abbreviations

TB: Tuberculosis
HIV: Human immunodeficiency virus
WHO: World health organization
ADR: Adverse drug reactions
MDR: Multi drug resistance
MTB: Mycobacterium tuberculosis
HHV6: Human herpes virus type 6
CADR: Cutaneous adverse drug reactions
DRESS: Drug reaction with eosinophilia and systemic symptoms
DIHS: Drug induced hypersensitivity syndrome
SJS: Stevens Johnson syndrome
TEN: Toxic epidermal necrolysis
BSA: Body surface area
HLA: Human leukocyte antigen
GSTM1: glutathione-S-transferase M1
NAT2: N-acetyltransferase 2
CYP2E1: Cytochrome P450 2E1
RIF: Rifampicin
INH: Isoniazid
ETH: Ethambutol
PZA: Pyrazinamide
LTT/LTA: Lymphocyte transformation test/assay
Chapter 1: Introduction and Literature review
1: Literature review and background to the study

1.1. Tuberculosis

Tuberculosis (TB) is a worldwide infectious disease, caused by *Mycobacterium tuberculosis* (MTB). Commonly MTB affects the lungs however other organs can also be affected dependent on the person’s ability to control the primary infection (Ghon focus). In 2013, there were 9 million people globally who developed TB. Of these, approximately 5.15 million were men, 3.3 million were women and 0.55 million were children. The majority of the reported TB cases were in Asia (56%) and Africa (29%) (World Health Organization 2014). South Africa was among the six countries with the highest absolute number of incident cases of TB with estimated absolute incident cases of 410000–520000 in 2013. The other countries were India (2.0 million–2.3 million), China (0.9 million–1.1 million), Nigeria (340 000–880000), Pakistan (370000–650000 ) and Indonesia (410000–520 000) (World Health Organization 2014). Considering incident rates, South Africa with 560 (776-980) new cases of TB per 100 000 population remained in the top ten countries with the highest estimated population based incidence rates for 2013. Eight of the top ten countries with high population based incidence rates were on the African continent whose people appear to carry the global population burden of TB (World Health Organization 2014).

Tuberculosis is one of the leading causes of death in the developing world. Due to human immunodeficiency virus (HIV) infection and poor socio-economic conditions in these regions, global attempts to control TB have been minimally effective and the incidence continues to increase (Department of Health Republic of South Africa 2014). In 2013 there were 1.5 million estimated TB deaths. Approximately 60% (900 000) of those dying from TB were men, 510 000 were women and 90 000 were children. African, South East Asian and Western Pacific WHO regions accounted for more than 75% of the TB deaths (World Health Organization 2014). This data excludes cases that
were missed by the notification health system, mainly in the developing world. It is evident from these statistics that TB remains one of the major threats to global health.

The HIV pandemic has resulted in a steep increased trajectory of cases co-infected with TB worldwide. Of the 9 million TB cases reported in 2013, 1.1 million (13%) were co-infected with HIV. Africa was the WHO region with the highest number of TB cases living with HIV (World Health Organization 2014). It was estimated that approximately 34% of TB cases were co-infected with HIV in Africa, accounting for 78% (800 000) of TB-HIV co-infection worldwide (World Health Organization 2014). WHO data show that 1.5 million people died from TB in 2013, and 360 000 (24%) of these deaths were in people who were co-infected with HIV (World Health Organization 2014). Despite constituting only 0.7% of the world’s population, South Africa accounts for about 25% (300 000) of the estimated global caseload of HIV associated TB (Wood et al. 2011).

The annual risk of acquiring TB in an HIV infected individual is 10% compared to a lifetime risk of 10% in an HIV-unaffected counterpart (Department of Health Republic of South Africa 2014). Infection with HIV increases the risk of dissemination of recent MTB infection and of reactivation of latent MTB infection by 5 to 15% annually (Department of Health Republic of South Africa 2014).

The burden of HIV and TB co-infection has resulted in multiple new TB management problems, including an increase in reported cases of multi drug resistance (MDR) TB. Wells and colleagues reported the association of HIV and (MDR) TB which resulted in complexity in the management of TB patients and hence poor infection control (Wells et al. 2007). The risk factors in HIV and TB co-infected patients for developing MDR TB were advanced immunosuppression, poor adherence to first line TB medication including the intermittent use of TB treatment, drug interactions, adverse drug reactions and poor gastrointestinal absorption of TB drugs (Wells et al. 2007).
1.2. Adverse drug reactions

There are various definitions for what constitutes an adverse drug reaction (ADR). In 1998, Pirmohamed and colleagues defined ADR as 'unpleasant effects of the drug beyond its expected therapeutic effects which occur during clinical use (Pirmohamed et al. 1998). The term adverse drug effect (ADE) and ADR are often used interchangeably to mean the same thing but the ADE is the expected effect of the drug and an ADR is an unexpected reaction that occurs in a patient (Aronson & Ferner 2005).

Adverse drug reactions were initially divided into type A (augmented pharmacology) or type B (bizarre, idiosyncratic). Type A (Augmented) reactions represent an augmentation of the pharmacological actions of a drug. They are predictable, dose dependent and are therefore readily reversible on reducing the dose or withdrawing the drug. Type A reactions account for the majority of ADRs and includes side effects and toxic effects.

Type B (Bizarre) reactions in contrast are rare, bizarre, unpredictable and are not dose dependent nor related to known drug pharmacology. They include immune mediated hypersensitivity reactions (IgE-mediated urticaria and immune complex vasculitis) and idiosyncratic reactions which are severe and life threatening such as SJS/TEN and DRESS where the pathogenesis is not clear-cut.

The importance of time-dependent reactions that occur after prolonged or chronic use, on drug withdrawal, or with a delayed action relative to when the drug was used need additional classification groups, as does drug failure. Type C (Chronic) reactions are related to time on medication and cumulative dose (glucocorticoid suppression of hypothalamic-pituitary-adrenal axis by glucocorticoid). Type D (Delayed) reactions becoming apparent sometime after the use of the drug and include teratogenesis and carcinogenesis. They are often dose-related. Type E (Withdrawal) reactions occur when the drug is withdrawn for whatever reason. Type F (Failure) reactions occur because of drug interactions leading to failed therapy. They are dose related. (Todd 2006; Edwards & Aronson 2000). ADR are usually diagnosed on clinical grounds from the temporal relation between the start and finish of drug treatment and the onset and resolution of the reaction. A culprit drug is identified if the signs and symptoms of ADR occurred after initiating the drug and resolves after withdrawing the drug and recur again on re-challenge with the same drug.
Adverse drug reactions contribute substantially to patient morbidity and hospitalization in South Africa. This is added to by the burden of HIV and TB co-infection. A South Africa study showed that HIV-uninfected persons are less likely to be admitted to hospital with adverse drug reactions compared to those who are HIV-infected (Mehta et al. 2008). Polypharmacy (more than 7 drugs) commonly ARVs, anti-tuberculosis drugs and co-trimoxazole were the main implicated drugs in most of the ADR admissions and deaths in four South African hospitals (Mouton et al. 2014). Mouton and colleagues reported drug induced renal failure and drug-induced liver injury were the most common adverse drug reactions related to death in HIV patients admitted to hospital for ADRs in the same survey of the 4 hospitals in South Africa (Mouton et al. 2014). Of the 24 patients who developed drug-induced renal failure, tenofovir was the most commonly implicated culprit drug in 14 (61%) cases followed by co-trimoxazole in 3 cases, rifampicin in 2 cases, furosemide in 2 cases, co-amoxiclavulanic acid in 2 cases and ibuprofen, enalapril, spironolactone, ciprofloxacin, aciclovir and indomethacin 1 case each. Ten patients developed drug-induced liver injury. Seven cases were due to anti-TB drugs (rifampicin, isoniazid and/or pyrazinamide) and 3 cases were due to co-trimoxazole either alone or together with other drugs. Fluconazole, erythromycin and sodium valproate accounted for 1 case each (Mouton et al. 2014). This data reflects the significant role played by anti-tuberculosis drugs in HIV associated ADR.

1.3. Cutaneous adverse drug reactions
A cutaneous adverse drug reaction (CADR) is the skin manifestations of an adverse drug reaction. There are different phenotypes of CADR ranging from mild self-resolving reactions to severe life threatening ones. Essentially any skin disease can be a manifestation of an adverse cutaneous reaction. Among the milder phenotypes are, exanthematous drug eruptions; IgE mediated reactions like urticaria; photo accentuated drug reactions; classic fixed drug reaction; vasculitis; neutrophilic drug reactions like acute generalized exanthematous pustulosis (AGEP) and acute febrile neutrophilic dermatoses (Sweet’s syndrome). The severe or life threatening drug reactions include drug reaction with eosinophilia and systemic symptoms (DRESS) also referred to as
drug induced hypersensitivity syndrome (DIHS); generalized bullous fixed drug eruptions (GBFDE); Stevens-Johnson syndrome (SJS); toxic epidermal necrolysis (TEN) and lichenoid drug reactions (LDR).

Exanthematous, maculopapular or morbilliform drug reactions mostly occur 7 to 14 days after starting medications or earlier in cases of re-introduction of the same offending medication. Clinically they present with an erythematous, maculopapular, measles-like eruption (Figure 1), urticarial plaques or annular, targetoid lesions. The mucosal surfaces are spared. The rash resolves within one or two weeks with no systemic symptoms, often despite ongoing treatment.

Figure 1: Morbilliform rash

Urticaria (Figure 2) is characterized by transient, erythematous, infiltrated papules and plaques with no epidermal change. The lesions last for less than 24 hours and resolve with no epidermal or post inflammatory changes. Angioedema (Figure 3) is acute oedema of dermal, subcutaneous and mucosal tissues and can be life-threatening if associated with asphyxia. Anaphylaxis is an acute life threatening type I hypersensitivity or IgE dependent drug reaction characterized by systemic manifestations including
hypotension and tachycardia which may occur together with or without urticaria and angioedema (Kemp et al. 2008).

Figure 2: Urticaria

Figure 3: Angioedema

Photosensitivity drug reactions (Figure 4) could either be photo-toxic (non-immune) or photo-allergic (immune mediated). The regions of the body affected are the sun-exposed surfaces of the face (forehead, zygoma, nose, lower lip and chin), the ears and cervical triangle. Sparing of the submental, posterior auricular and periorbital regions is
strongly supportive. Photo-toxic drug reactions usually occur within hours after exposure to the culprit drug together with light. This clinically resembles exaggerated or acute sunburn and can occur in any person taking a drug known to cause phototoxic reactions. Photo-allergic drug reactions usually develop within days of exposure to the culprit drug together with ultraviolet radiation. They are type IV hypersensitivity reactions and clinically may resemble eczema or lichenoid reactions (Glatz & Hofbauer 2012).

Figure 4: Photosensitivity drug reaction

Lichenoid drug reactions (LDR) occur within months to years of exposure to the culprit drug but may require exposure to the culprit drug together with ultraviolet radiation. It is clinically characterised by burning, itchy, lilac macules that progresses to become violaceous to purple, flat-topped, scaly papules often involving the flexural surfaces. Both the skin and mucosae may be involved. It resolves with or without post inflammatory hyperpigmentation on withdrawal of the drug (Figure 5).
A fixed drug eruption may occur on the skin or mucosae within minutes of culprit drug ingestion. They clinically presents as an itchy, well circumscribed, round, erythematous to purple patch often with an outer rim of erythema in the active state. They can blister and they resolve leaving slatey grey-black post-inflammatory hyperpigmentation (Figure 6). They occur as solitary or multiple patches. Re-exposure to the offending drug leads to recurrence at the same site or the development of new lesions elsewhere. Occasionally it can be life-threatening and confused with SJS/TEN if it is bullous and generalized (Figure 7) (Lipowicz et al. 2013).
SJS and TEN are severe, potentially life threatening drug reactions that occur between one to two weeks after exposure to the culprit drug. They are clinically characterized by mouth, eyes and genitalia involvement together with epidermal necrosis and varying degrees of detachment on a background of erythema. In SJS, the skin detachment is <10% body surface area (BSA) (Figure 8) compared to >30% BSA in TEN (Figure 9). SJS/TEN overlap is characterized by epidermal necrosis of 10%-30% (Roujeau 1994). SJS and TEN may be associated with systemic disease or with complications that could either be acute or chronic. Acute complications that account for the high mortality include bacterial systemic infection, metabolic dysfunction and fluid loss. Mortality risk can be assessed on the day of admission and again 3 days later by applying the TEN-specific severity-of-illness score (SCORTEN) (Guégan et al. 2006). Nail dystrophies, dyspigmentation, sicca symptoms, mucosal adhesions, oesophageal strictures, hypertrophic scars and blindness are chronic anticipated sequelae in some cases especially in those with severe disease (Roujeau 1994).

The mortality rate varies. Studies have shown that SJS mortality ranges between 0% and 12%, while that of TEN ranges from 30% to 46% (Sekula et al. 2013; Saka et al. 2013; Kannenberg et al. 2012; Roujeau & Stern 1994). The mortality rate may increase depending on the extent of the BSA involved, the patient’s age and other SCORTEN parameters (Harr & French 2010). A large prospective cohort study of severe SJS/TEN requiring hospitalization from several centres in Europe, reported a 6 week mortality rate of 23% overall; 12% for SJS, 29% for SJS/TEN overlap and 46% for TEN (Sekula et al. 2013). In this study a history of malignancy and the older age of the affected patients contributed to the higher mortality reported. In a prospective cohort study undertaken in South Africa, a comparable mortality rate of 24% for all forms of SJS and TEN was reported. When sub analysis were done, the TEN mortality rate was 40% which was statistically significant (p=0.001) when compared to the 0% of SJS (Kannenberg et al. 2012). Comparable findings were reported for sub-Saharan Africa in a retrospective study of a cohort collected from several African countries in which 74% were less than 50 years of age. An overall mortality of 12% was found; 5% for SJS, 9%
for SJS/TEN overlap and 41% for TEN. HIV-infection was comorbidity in 73% of the 22 deaths (Saka et al. 2013).

Figure 8: Stevens-Johnson syndrome

Figure 9: Toxic epidermal necrolysis

DRESS/DIHS is a severe CADR which occurs two to six weeks after exposure to the offending drug. It is clinically characterized by fever, oedema (especially of the face), a morbilliform rash (Figure 10), lymphadenopathy, leukocytes abnormalities and internal organ involvement. The most commonly affected internal organ is the liver which may result in severe hepatitis, liver failure, encephalopathy and sometimes death. A mortality rate for DRESS/DIHS was reported to be 10% from RegiSCAR data from around the world (Kardaun et al. 2013).
2. Pathogenesis

2.1. Adverse drug reaction pathogenesis

Multiple factors influence the occurrence of disease, its clinical picture and outcome. This concept best explains the pathogenesis of unexpected reactions to drugs. Only a proportion of those exposed to an infectious agent will develop clinical disease, and similarly not all those exposed to a drug develop a drug reaction. Other cofactors of causation need to be variably present, which, on their own, do not necessarily produce the effect (Todd 2006; Sullivan & Shear 2001).

The pathogenesis of CADRs is slowly unraveling. The mechanism by which a drug leads to immune mediated adverse reaction (pharmaco-immune concept, modified Gel and Coombs hypersensitivity reactions) can be explained by either hapten hypothesis or P I concept. The drug or its metabolites must be recognized by the immune system in the context of self. Several mechanism have been shown to be involved in drug-major histocompatibility complex (MHC)-peptide binding on antigen-presenting cells for initiation of an immune response, both innate and adaptive and cause localized or systemic reactions. The drug acts as a hapten (the chemically reactive drug itself binds
covalently to carrier proteins which may include the MHC-peptide complex), prohapten (the drug must be metabolised to a reactive hapten) and non-hapten (non-covalent, labile binding to the MHC-peptide complex) or the p-l concept (pharmacological interactions of drug with immune receptors concept, drugs can bind directly to T-cell receptors TCR). On presentation or binding to T-cells via shared or restricted TCRs (HLA-drug-TCR interaction), multiple cellular triggers are required for the propagation of an immune response resulting in an expansion of lymphocyte clones (T and B cells), the releases of cytotoxic proteins (granulysin, perforin, granzyme etc.), and apoptosis (Pichler et al. 2010). All reactions are T-cell–regulated, but the effect is dependent on antibody-mediated effector functions or more T-cell/cytokine dependent functions. (T and B cells) and cause localized or systemic reactions The “danger” hypothesis proposes that following initiation of the acquired immune system, tolerance (possibly involving T-reg cells) is the normal default response and that “danger” signals are necessary for propagation and the subsequent development of an immune response. “Danger” signals can be produced by the innate immune system or any inflammatory episode as a result of cellular stress (e.g., drug/toxic metabolites, cell damage, bacterial products) (Todd 2006; Uetrecht 1999).

The cutaneous reactions that can occur as a result of immune stimulation by a single drug are influenced by the efferent output following T-cell activation. Preferential activation of T-cell populations with distinct functions can lead to cytotoxic T-cells (CD4+ cells in morbilliform reactions, CD8+ cell in vesico-bullous reactions) can orchestrate the skin reaction by release of cytokines/chemokines which in turn activate or recruit specific cells into the skin (interleukin 4 and 5 for eosinophil infiltrates, interleukin 8 for neutrophil infiltrates, interferon-γ for monocyte infiltrates) (Pichler et al 2010).

The dynamic synergistic interaction of constitutional and acquired factors, determines whether one develops a drug reaction. The unique combination of cofactors present at the time of drug exposure in a particular individual may explain why an adverse event may not recur on re-challenge.
The relationship between drug reactions and immunogenetics was recently proposed by Chung and colleagues who showed that certain polymorphisms of the HLA genes predispose to drug hypersensitivity reactions. These included HLA-B*15:02 and carbamazepine (CBZ)-induced SJS/TEN and HLA-B* 58:01 and allopurinol-induced SJS/TEN and DRESS (Chung et al. 2007). More recent studies have shown that drugs presented by specific HLA alleles are recognized by specific T-cell receptors leading to activation of cytotoxic T lymphocytes and cytotoxic signal expression (Chung et al. 2008). These HLA genetic associations with immune-mediated cutaneous drug reactions are complex, drug specific and ethnicity specific.

HLA-B*15:02 has been shown to be present in 100% of Han Chinese who develop CBZ-induced SJS/TEN but in only 3% of CBZ-tolerant patients and in 8.6% of the general population of Han Chinese from Taiwan (Hung et al. 2006; Chung et al. 2004). HLA-B*15:02 is present in 75% of Malay patients with CBZ-induced SJS/TEN but in only 15.7% of normal controls (Chang et al. 2011). In a study done in Europe only four cases (25%) were HLA-B*15:02 allele positive among 12 cases of CBZ-induced SJS/TEN and all four were of Asian origin (Lonjou et al. 2006). Screening for HLA-B*15:02 before prescribing CBZ in Taiwan has significantly reduced the number of cases of SJS/TEN in the country (Ferrell & McLeod 2008). This is probably applicable for Malaysia and for Asians living abroad.

HLA-B*58:01 was reported to be present in all 51 patients (100%) with allopurinol-induced SJS/TEN and DRESS in Han Chinese but in only 15% (20 of 135) of the allopurinol tolerant group and 20% (19 of 93) of the general healthy population from Taiwan (Hung et al. 2005). In Thai population, twenty seven (100%) allopurinol-induced SJS/TEN patients who were examined carried HLA-B*58:01 whereas only seven (13%) of the tolerant control patients had this allele (Tassaneeyakul et al. 2009).

HLA-B*57:01 was reported as present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients from a Western Australian cohort study (Mallal et al. 2002).
The presence of HLA-B*13:01 was proposed as a predictor of dapsone hypersensitivity in patients with leprosy. It was present in about 2% to 20% of Chinese persons with leprosy and dapsone hypersensitivity reactions, 1.5% of a similar cohort in Japan, 1% to 12% of Indians with leprosy and dapsone hypersensitivity, and 2% to 4% of a similar Southeast Asian cohort but 0% in European and African cohorts (Zhang et al. 2013).

Clearly there are population, drug and CADR specific HLA haplotypes that are not generalizable globally.

2.2. Pathogenesis of adverse reactions to TB drugs
Sharma and colleagues have demonstrated the association of HLA class II haplotypes associated with anti-tuberculosis drug induced liver injury. These include HLA-DRB1*03 for isoniazid, HLA-DQA1*01:02 for rifampicin, and HLA-DQB1*02:01 for ethambutol (Sharma et al. 2005).

Other studies have shown the association between isoniazid-induced hepatitis and genetic polymorphisms of drug metabolism enzymes, including cytochrome P450 2E1 (CYP2E1), N-acetyltransferase 2 (NAT2), and glutathione-S-transferase (GST) M1 (GSTM1). Individuals with CYP2E1 gene activity are able to convert isoniazid to toxic metabolites, including hydrazine, while GSTM1 and NAT2 convert the toxic metabolites to non-toxic metabolites (Huang et al. 2002). Huang and colleagues reported polymorphisms of the NAT2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. N-acetyltransferase 2 is responsible for acetylation of INH toxic metabolites. Polymorphisms promoting slow acetylators have a more than two-fold risk of developing INH-induced hepatitis when compared with fast acetylators in a Taiwanese population (Huang et al. 2002). The following risk factors for the accumulation of hydrazine, the toxic metabolite of isoniazid, have been reported by Fukino and colleagues and include NAT2 slow acetylator phenotype, high concentration of serum rifampicin, and GST M1 null genotype (Fukino et al. 2008).
The clinical presentation of TB-associated CADR varies with different studies elaborating different types of CADR due to TB drugs. Tan and colleagues reported on 47 patients who developed TB associated CADR. A morbilliform eruption was seen in 72.3%, 8.5% had urticaria and the rest developed exfoliative dermatitis, erythema multiforme and a lichenoid eruption (Tan et al. 2007). Lehloeny and colleagues reported on the spectrum of TB-medication associated severe CADR requiring hospital admission. The spectrum of CADR included DIHS/DRESS (38%), SJS (26%), TEN (20%), SJS/TEN overlap (8%), and lichenoid drug reactions (5%) (Lehloeny et al. 2011). In a study from Togo, among 8 cases of severe CADR due to rifampicin and isoniazid, 3 developed SJS and 5 developed TEN (Pitche et al. 2005).

The clinical presentation of anti-tuberculosis associated drug reactions is likely to be immune-mediated, since re-challenging with the same drug typically shortens the incubation period and results in more severe manifestations (Hung et al. 2006; Chung et al. 2004).

The CADR are more frequent to occur in HIV infected patients compared to un-infected person. A South Africa study showed that HIV-uninfected persons are less likely to be admitted to hospital with adverse drug reactions compared to those who are HIV-infected (Mehta et al. 2008). Polypharmacy (more than 7 drugs) commonly ARVs, anti-tuberculosis drugs and co-trimoxazole were the main implicated drugs. There is a high incidence of TB-associated severe CADR in HIV-infected patients in the South African population (Marks et al. 2009). A study from a primary care clinic in South Africa showed that severe CADR to anti-tuberculosis drugs occurred in 13% of non-HIV-infected patients and 27% of those who were HIV-infected (Marks et al. 2009). Lehloeny and colleagues reported that 92% of the severe TB-associated CADR admitted to a tertiary hospital in South Africa from January 2001 to April 2009 were HIV co-infected patients (Lehloeny et al. 2011).
3. Tuberculosis management

First line anti-tuberculosis therapy with rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB) is effective with excellent cure rates and results in less recurrence of TB after treatment (Rezakovic et al. 2014). However it is associated with CADRs. Several studies demonstrate a significant increase of TB CADRs due to the increased burden of TB co-infected HIV individuals requiring treatment. From a retrospective study done in Penang hospital an incidence rate of 5.7% for CADRs was reported. Pyrazinamide was the commonest offending drug (2.38%), followed by streptomycin (1.45%), ethambutol (1.44%), rifampicin (1.23%) and isoniazid (0.98%) (Tan et al. 2007). CADRs were more likely to occur in HIV-infected people with polypharmacy (>7 drugs) and those with autoimmune disorders (Tan et al. 2007). In a similar retrospective study done in South Africa, among patients admitted to hospital with severe CADRs, rifampicin was the most commonly implicated drug, followed by isoniazid, pyrazinamide and lastly ethambutol. Respectively these drugs were responsible for 57%, 22%, 13% and 4% of severe CADRs (Lehloenya et al. 2011).

Adverse drug reactions caused by anti-tuberculosis drugs can lead to interruption of therapy, treatment failure and/or the risk of drug-resistance (Rezakovic et al. 2014). Drug resistance complicates the management of tuberculosis and represents one of the most important emerging challenges in the control of TB worldwide (Glaziou et al. 2013).

The consequences of TB-associated CADR are thus significant and include increased mortality and morbidity and the need for second line anti-tuberculosis therapy.

Second line anti-tuberculosis therapy is associated with a higher incidence of toxicities and is less effective (Rezakovic et al. 2014). Despite this, it is still considered as a treatment option for multidrug resistance TB and repeat infections. These second line anti-tuberculosis drugs are associated with their own range of severe CADRs. They are also associated with multiple drug hypersensitivity reactions which pose a major long term therapeutic challenge when needed for patients with proven allergies to first line
agents. In a study from South Africa among patients admitted with CADRs, streptomycin and ofloxacin were related to multiple drug hypersensitivity CADRs in 4% (1/23) of the cases each (Lehloenya et al. 2011).

Switching to second line anti-tuberculosis treatment results into poorer compliance due to the anxiety of taking treatment after experiencing a severe CADR together with the longer duration of treatment required to achieve cure and the higher side effect profile in comparison to first-line agents (Rezakovic et al. 2014).

As a consequence of significant adverse health effects, suboptimal treatment and poor outcome associated with the use of the second line treatment, there is a need for re-challenge to identify the offending drug and remove it from the primary treatment regimen. Despite the associated risks of a recurrence of a severe CADR, first line treatment is necessary as it provides better infection control. Ultimately the balance between the benefit of re-exposure and risk of severe CADR and suboptimal treatment has to be weighed before re-challenge (Lehloenya & Dheda 2012; Lehloenya et al. 2011).

4. Drug causality and re-challenge
Clinical assessment is commonly used to indicate the causality of ADRs if there is a history of a recent new drug having been administered. Establishing drug causality becomes very difficult when there is more than one drug administered at the same time such as with TB drugs or when there is polypharmacy in cases of multiple co-morbidities such as HIV-TB co-infection. In these settings there is a need to test for drug causality.

There are various methods of determining drug causality. These modalities could either be performed \textit{in vivo} or \textit{in vitro}. \textit{In vitro} tests includes lymphocyte transformation test/assay (LTT/LTA), CD69 up-regulation flow cytometry test and cytokine production assays. LTT/LTA is one of the most widely used laboratory tests for the identification of the culprit drug following ADR/CADR. The sensitivity and specificity of LTT/LTA varies
with the drug being evaluated, experience of the laboratory technicians performing the test, type of CADR being investigated and the subject (Pichler & Tilch 2004). Lochmatter and colleagues reported that, LTT/LTA has a low specificity of 85% and sensitivity (60-70%) in comparison to other methods such as oral provocation test (Lochmatter et al. 2009). Suzuki et al evaluated the usefulness of LTT/LTA for determining the offending anti-tuberculosis drugs causing side effects in comparison to the gold standard (oral provocation test). They reported that the sensitivity of LTT/LTA was only 14.9% in identifying the offending anti-tuberculosis drugs. (INH 14.3%, RIF 13.6%, EMB 14.3%, PZA 0%) (Suzuki et al. 2008). Despite being used for more than 30 years LTT/LTA is still considered experimental due to its limitations.

*In vivo* modalities are the oral provocation test and skin testing (patch, prick and intradermal). These are re-challenge procedures where the patient is re-exposed or re-introduced to the drug which previously caused the adverse drug reaction.

Oral provocation test also known as controlled challenge, re-exposure test, and drug re-challenge test is the controlled administration of a drug in order to diagnose drug reaction causality. It could entail either the administration of the offending drug *per se* or a structurally or pharmacologically related compound (Aberer et al. 2003). Oral provocation testing remains the “gold standard” in establishing drug causality relative to a specific ADR (Kurniadhi et al. 2006).

An oral provocation test has its own limitations and a negative provocation does not completely prove tolerance in the future or exclude the drug as the culprit if other associated co-factors and comorbidities are absent during the oral challenge or if it is done at too low a dose and not over a long enough period of time. A positive provocation test similarly might not indicate lifelong hypersensitivity for similar reasons. The severity of CADR recurrence is also not predictable (Aberer et al. 2003).

In our cases and controls re-challenge followed a specific protocol in which the patients underwent serial testing (patch, skin prick and then oral) over a 2 week period. If any
test caused a reaction re-challenge was halted. If there was no reaction the patient was maintained on the drug to which they had been re-challenged for the period of the TB treatment. This re-challenge was not done for academic reasons but to re-introduce the best medication for controlling TB especially in immunosuppressed patients.

Skin testing with the suspected offending drug may be useful in determining the cause of a CADR. This could either be in the form of a patch, prick or intradermal test. These tests also pose a risk of eliciting the initial CADR. It is postulated that the severity of the re-challenge reaction should be less severe compared to oral re-challenge as there is exposure to lower concentrations the offending drug. This is not proven to be the case in clinical practice. Shebe and colleagues reported recurrence of drug reaction with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man (Shebe et al. 2014).

Skin test sensitivity (70%) and specificity is still low especially in non-immediate reactions even when used in its maximum concentration compared to oral provocation testing (Rerkpattanapipat et al. 2011).

Genes that control the immune response in humans, especially those within the major histocompatibility complex, have been shown to modulate the expression of diseases induced by exogenous triggers (infections, foreign protein, environmental allergens or medication)(Miura et al. 2009; O’Connell et al. 2009; Louie et al. 2004). The human genome, mainly HLA, has been well documented to have a role in modulating infectious diseases such as TB and HIV (Louie et al. 2004). HLA class I and II (HLA-B8, HLA-B15 and HLA-DR2) have been shown to be associated with a risk of active TB while a HLA-DR6 association decreases the risk of TB (Louie et al. 2004). HLA class I has been associated with HIV control and progression. HLA-B* 58:01 reduces viral load replication and induces cytotoxic T cell lymphocyte response in HIV-infected persons and is associated with good prognosis. HLA-B*58:02 is associated with rapid progression of the disease and poor prognosis (Miura et al. 2009; O’Connell et al. 2009).
5. Summary
At present there is no practical screening test to identify those susceptible to tuberculosis drug-associated reactions and the susceptibility genes remain unknown. Various studies have shown immunogenetics to be population and drug specific (Chung & Hung 2012). We have a well characterized confirmed severe CADR population in Cape Town. The culprit drug has been confirmed through patch and/or prick testing and/or oral drug re-challenge. They are an ideal population cohort to investigate the immunogenetics of anti-tuberculosis drug-associated CADR.

Challenges to this study will be to tease out the HLA contributions of HIV and TB to our findings. The use of a group of drug tolerant patients who also have HIV and TB we hope will resolve their contribution.
REFERENCES


Chantarangsu, S. et al., 2009. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics., 19(2), pp.139–46.


Chapter 2: Publication-ready manuscript
GENOMICS STUDY OF ANTI-TUBERCULOSIS DRUG-INDUCED HYPERSENSITIVITY REACTIONS

Khadija A. Shebe¹, Gail Todd², Wen-Hung Chung³, Shuen-Iu Hung⁴, Rudzani Muloawa⁵, Rannakoe J. Lehloenya¹.

¹Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa
²Department of Medicine, University of Cape Town, Cape Town, South Africa
³Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung and Linkou Branches, College of Medicine, Chang Gung University, Taiwan
⁴Institute of Pharmacology, College of Medicine, National Yang-Ming University, Taipei, Taiwan
⁵Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa

Correspondence: Khadija Ahmed Shebe. Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Email: kudi19tz@yahoo.com

Abbreviations: CADR, cutaneous adverse drug reactions; HLA, human leukocyte antigen; TB, tuberculosis; HIV, human immunodeficiency virus; ADR, adverse drug reaction; DRESS, drug reactions include drug reaction with eosinophilia and systemic symptom; DIHS, drug induced hypersensitivity syndrome; SJS, Stevens Johnson syndrome; TEN, toxic epidermal necrolysis; RIF, rifampicin; INH, isoniazid

Prepared as for submission to the Journal of Investigative Dermatology
ABSTRACT

All first-line anti-tuberculosis drugs can be associated with all phenotypes of cutaneous adverse drug reactions (CADR). Second-line drugs are associated with much poorer outcomes. Thus, identifying the offending drug in poly-pharmacy is difficult. Re-challenge with the drug is the gold standard in identifying the offender, however poses unacceptably high risk of CADR recurrence. Population and drug-specific genomics help identify those susceptible to adverse reactions to a drug facilitating avoidance of the drug. We aimed to investigate the genomic susceptibility in patients with confirmed rifampicin and or isoniazid-associated hypersensitivity reactions using both genome-wide association studies and candidate gene approaches. There were no significant candidate genes between our cases and study controls. However, when compared to the general population of black South Africans, HLA-B*58:02 (OR=3.6; 95% CI: 1.4-8.99) and HLA-DRB1*09:01 (OR=15.3; 95% CI: 2.1-113.1) were significantly more prevalent among our cases. HLA-B*58:02 and HLA-DRB1*09:01 may be associated with rifampicin and isoniazid-associated CADR. Alternately HLA-B*58:02 may be associated with HIV status rather than CADR. A sufficiently powered study is needed to confirm this association.
INTRODUCTION

Tuberculosis (TB) is a common worldwide infectious disease. In 2013, 9 million people globally developed TB. South Africa had the 6th highest estimated incidence rate of TB (410000–520000 per 100 000 population). TB is a leading cause of mortality in the developing world, particularly in populations with a high HIV burden. In 2013 approximately 13% of the 9 million cases worldwide were HIV co-infected (World Health Organization 2014). The pandemic of HIV and TB co-infection has resulted in multiple new problems, including a higher incidence of cutaneous adverse drug reactions (CADR). The offending drugs often include anti-retroviral drugs, anti-tuberculosis drugs and other drugs used for management of HIV-associated opportunistic infections (Mouton et al. 2014; Marks et al. 2009; Mehta et al. 2008; Pozniak et al. 1992).

TB-associated CADRs range from mild, self-resolving to severe and life threatening reactions. Some are severe enough to warrant interruption of therapy, such as drug reaction with eosinophilia and systemic symptoms also called drug induced hypersensitivity syndrome (DRESS/DIHS); Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (Lehloenyana & Dheda 2012).

Recent studies have shown that drugs, presented by specific human leukocyte antigen (HLA) alleles, are recognized by specific T cell receptors leading to activation of cytotoxic T lymphocytes and cytotoxic signal expression (Chung et al. 2008). These HLA genetic associations with immune-mediated cutaneous drug reactions are complex, drug specific and ethnicity specific. HLA-B*15:02 is found in 100% of Han Chinese who develop carbamazepine (CBZ) -induced SJS/TEN (Hung et al. 2006; Chung et al. 2004). It is also found in 75% of Malay patients with CBZ-induced SJS/TEN (Chang et al. 2011). HLA-B*58:01 is found in 100% of Han Chinese with allopurinol cutaneous adverse drug reaction including SJS/TEN and DRESS (Hung et al. 2005). HLA-B*5701 is found in 78% of the Western Australian cohort with abacavir hypersensitivity (Mallal et al. 2002). HLA-B*13:01 is a predictor of dapsone hypersensitivity in Chinese persons with leprosy (Zhang et al. 2013).
Sharma and colleagues have demonstrated the association of HLA class II haplotypes associated with anti-tuberculosis drug induced liver injury. These include HLA-DRB1*03 for isoniazid, HLA-DQA1*01:02 for rifampicin, and HLA-DQB1*02:01 for ethambutol (Sharma et al. 2005). Other studies show the association between isoniazid-induced hepatitis and genetic polymorphisms of drug metabolism enzymes, including cytochrome P450 2E1, N-acetyltransferase 2 (NAT2), and glutathione-S-transferase M1 (GSTM1) (Huang et al. 2002). Fukino and colleagues included NAT2 slow acetylator phenotype, high concentration of serum rifampicin, and GST M1 null genotype as risk factors for anti-tuberculosis-induced hepatitis (Fukino et al. 2008).

First line anti-tuberculosis therapies, while effective; are associated with CADRs (Rezakovic et al. 2014). Lehloenya and colleagues reported that the spectrum of TB-associated severe CADRs which required admission in South Africa included DIHS/DRESS (38%), SJS (26%), TEN (20%), SJS/TEN overlap (8%), and lichenoid drug reactions (5%) (Lehloenya et al. 2011). Among these patients, rifampicin was the most commonly implicated drug, followed by isoniazid, pyrazinamide and lastly ethambutol. Respectively these drugs were responsible for 57%, 22%, 13% and 4 % of CADRs (Lehloenya et al. 2011).

A study done in a primary care clinic in South Africa reported that CADRs to anti-tuberculosis drugs occurred in 13% of non-HIV-infected patients and 27% of those who were HIV-infected (Marks et al. 2009). Lehloenya and colleagues also reported a high association, 92% of severe TB-associated CADRs admitted between January 2001 and April 2009 were HIV co-infected patients (Lehloenya et al. 2011).

Adverse drug reactions caused by anti-tuberculosis therapy can lead to interruption of therapy, treatment failure and/or the risk of drug-resistance (Rezakovic et al. 2014). The consequences of TB-associated CADRs are thus significant and include increased mortality and morbidity and hence the need for second line anti-tuberculosis therapy.

Second line anti-tuberculosis therapy is less effective, has a higher incidence of toxicities (Rezakovic et al. 2014) and their own range of severe CADRs. As a consequence of significant adverse health effects, suboptimal treatment and poor
outcome associated with the use of the second line therapy, there is a need for re-challenge to identify the offending first line drug and remove it from the primary treatment regimen. Despite the associated risks of a recurrence of a severe CADR, first line treatment is necessary as it provides better infection control. Ultimately the balance between the benefit of re-exposure and risk of severe CADR and suboptimal treatment has to be weighed before re-challenge (Lehloenya & Dheda 2012; Lehloenya et al. 2011).

At present there is no practical screening test to identify those susceptible to tuberculosis drug-associated reactions and the susceptibility genes remain unknown. Various studies have shown immunogenetics to be population and drug specific (Chung & Hung 2012). We have a well characterized, confirmed severe CADR population in Cape Town. The culprit drug has been confirmed through patch and/or prick testing and/or oral drug re-challenge. They provided an ideal population cohort to investigate the immunogenetics of anti-tuberculosis drug-associated CADRs.

RESULTS

Demographic characteristics (Table 1)

We recruited a total of 44 participants for this study. The 14 cases all had re-challenge reactions to either RIF and/or INH. The 26 controls tolerated these drugs and comprised 12 patients with anti-tuberculosis drug-associated CADRs tolerant to RIF and INH on re-challenge (Group1a) and 18 cases with no CADRs but on TB medication (Group 1b).

The median age of our study population was 35 years with cases 32 years and controls 36 years (Group1a, 35 years and Group1b 36 years). There were more females amongst the cases (57%) compared to the controls (43% overall; Group1a, 50%; Group1b 39%). The majority of the patients were black, 31/44 (70%) and the remaining 13/44 (30%) were of mixed race origin. This ratio was similar for cases and both control groups.

Most of the study cohort was HIV positive accounting for 82% of patients. Eleven out of 14 (79%) cases were HIV-infected as were 25/30 (83%) of the controls. All 12 (100%) of
control Group1a were infected compared to only 13/18 (72%) of control Group1b. The median CD4 count of those cases who were HIV-infected was 149 cells/mm$^3$ (range: 74-329) and it was 171 cells/mm$^3$ (range: 76-323) among controls although Group1b, 300 cells/mm$^3$ (range 124-333) had a higher median CD4 count compared to Group 1a, 108 cells/mm$^3$ (range 39-141). Less than 50% of those who experienced CADRs were on ARVs (42% cases and 43% Group 1a controls). Seventy-two percent of those on TB medication who had not experienced CADRs (Group 1b) were on ARVs.

**Clinical characteristics:**

None of the cases or controls had a history of ADRs to any previous medication. No cases or controls that experienced CADRs to anti-tuberculosis drugs had been previously treated for TB. In contrast seven of the 18 controls who had not experienced CADRs had been previously treated for different forms of TB. All the cases were admitted to hospital for management of their drug reactions compared to 11/30 (37%) of the controls. The reasons for the admission of the controls ranged from other diseases to CADR due to either TB and/or other medications. Thirteen of the fourteen cases (93%) had DRESS on initial presentation and a single case of SJS. Amongst the controls 7/12 (58%) had DRESS, the rest had SJS (1), SJS/TEN overlap (1), TEN (1), and pseudoporphyria (1), while one CADR was unknown.

All cases and 12/30 (40%) controls (Group1a) were exposed to cover drugs during the process of re-challenge. Among those re-challenged, some had reaction to at least one of the cover drugs. The implicated drugs were moxifloxacin and ofloxacin among the cases and ethionamide, moxifloxacin and amikacin among the controls.

**Offending first-line drugs:**

Of the 14 cases that developed re-challenge reactions, 7 were due to RIF, 5 reacted to INH and 2 reacted to both RIF and INH independently. Only one control developed a re-challenge reaction, attributed to PZA on oral re-challenge. Three of the RIF-associated re-challenge reactions were on patch testing and 5 were on oral re-challenge. All 4 cases who developed INH-associated re-challenge reactions and the 2 who developed re-challenge reactions to both INH and RIF occurred on oral re-challenge. None of the
re-challenge reactions occurred following prick testing (Table S1). None of the re-
challenge reactions was life threatening. The skin changes resembled DRESS when
present. Itch (10/14), erythema (13/14) and rash (13/14) were the most frequent re-
challenge reactions amongst the 14 cases. Fever (8/14), hepatitis (6/14) oedema (5/14),
sore eyes (2/14) and eosinophilia (2/14) occurred less frequently.

**HLA genotyping:**

HLA-B genotyping was successfully done in most of our participants (Table 2 & 3). Due
to technical problems, breaks in the cold chain during sample transportation and
collection method used, most of the controls had poor quality and low DNA yields and
thus limited PCR product for analysis.

*Cases compared to RIF and INH tolerant controls.*

There were no significant associations observed between HLA genotype and CADR
when the cases were compared to the RIF and INH tolerant control population (Table 3).
Some genotypes did have an odds ratio that was greater than 1 when cases were
compared to tolerant controls; however, this positive association was not statistically
significant (Table 3). There were no HLA genotypes that showed a significant negative
association i.e. a protective effect (Table 3).

*Cases compared to the general South African black population*

HLA-B*58:02 (OR=3.6; 95% CI: 1.4-8.99) and HLA-DRB1*09:01 (OR=15.3; 95% CI:
2.1-113.1) showed significant positive associations with CADR when the cases were
compared to the general South African black population (Table 3 and 4). A positive
association (OR>1) that did not reach statistical significance emerged with other HLA
genotypes when comparing the cases and the general South African black population
(Table 5 and 6). There were no HLA genotypes that showed a significant negative
association i.e. a protective effect (Table 3).
**HLA-B genotype and the effect of HIV status**

Out of the 44 participants there were 36 who were HIV infected, 7 were HIV negative and the status of one was unknown. HLA-B*58.02 was found in 11 of the HIV infected cohort, it was found in 1 of the HIV negative cohort and for one HIV positive patient the HLA typing had failed and was not available. HLA-B*58.02 was not found to be statistically associated with HIV positive status (p=0.42). As there was no documentation of HIV status amongst the 200 general population historic controls the HIV association with HLA-B*58.02 could not be assessed. All study cases and controls had TB so this association with HLA-B*58.02 could not be computed.

**DISCUSSION**

To our knowledge, this is the first study to show an association between HLA-B*58:02 and HLA-DRB1*09:01 alleles and severe cutaneous adverse drugs reactions secondary to rifampicin and isoniazid in an African population. We found HLA-B*58:02 and HLA-DRB1*09:01 to be significantly more prevalent in patients who developed rifampicin and isoniazid-associated severe CADR as compared to a historic general South African black population. We found no significant associations between HLA genotype and rifampicin/isoniazid-associated severe CADR when we compared the cases to our study controls that had tolerated rifampicin and isoniazid. Considering the small sample size, the statistical significance for both alleles was associated with relatively tight confidence intervals.

It has been convincingly shown that HLA genotype can serve as a predictor of CADR. The best-known example is the 100% association of HLA-B*15:02 in carbamazepine-induced SJS/TEN in the Han Chinese populations. The same HLA-B*15:02 has been shown to have weaker associations in non-Asian populations (Ferrell & McLeod 2008). This association has led to a recommendation by the Food and Drug Administration (FDA) in the United States recommending that all patient of Asian descent should be screened for HLA-B*15:02 before initiating carbamazepine (Ferrell & McLeod 2008). This allele was not present in our patients or controls.
Other significant population and drug-specific HLA associations include HLA-B*58:01 in allopurinol-induced SJS/TEN in Han Chinese and Thai population (Tassaneeyakul et al. 2009; Hung et al. 2005); dapsone-induced DRESS/DIHS and HLA-A*31:01 in Chinese population (Zhang et al. 2013); abacavir-induced hypersensitivity syndrome and HLA-B*57:01 in western Australia (Mallal et al. 2002) and HLA-B*35:05 and nevirapine-associated CADR in Thailand population (Chantarangsu et al. 2009). None of these HLA-B alleles were detected or strongly associated with CADR, if present, in our study. Specific HLA alleles have also been identified for other forms of ADR not involving the skin. None of these HLA alleles were detected with CADR in our study. These studies highlight that HLA-ADR associations are population, drug and ADR phenotype specific.

Before the current study, to our knowledge, there was no data on HLA genotypes that are associated with CADR and anti-TB drugs in Africans. We identify 2 candidate HLA alleles that need confirmation of their association in African patients who develop rifampicin or isoniazid-associated CADR in larger studies. The value of identifying candidate alleles could lead to CADR preventative screening prior to initiating anti-tuberculosis therapy in black South Africans.

HLA-B*40:01 in Taiwan Han Chinese and HLA-B*07:02 in Caucasians have been found to be protective against CMZ-induced SJS/TEN (Hung et al. 2006; Alfirevic et al. 2006). Unfortunately we found no significantly protective HLA genotype for rifampicin/isoniazid-associated CADRs in our study.

We found that HLA-B*58:02 cases were more associated with clinical features suggestive of DRESS/DIHS. DRESS/DIHS was the prevalent phenotype of CADR, accounting for 93% of cases and only 53% of controls who experienced CADRs (Group 1a). This association is worth exploring in more detail to determine CADR subtypes and their relationship to HLA genotypes in the black South African population. Interestingly most of the re-challenge reactions were suggestive of DRESS/DIHS. No firm conclusion could be drawn as the reactions were not allowed to develop and the patient treated as soon as an adverse effect was noted during the re-challenge.
Three of the cases developed re-challenge reactions to rifampicin patch test and 10 were either due to oral rifampicin and/or isoniazid. Seven of our cases developed re-challenge reactions to rifampicin, 5 reacted to isoniazid and two to both drugs. HLA-B*58:02 was associated with both rifampicin and isoniazid-related cases. However, HLA-DRB1*09:01 was found in isoniazid related cases (one case due to INH and one case due to both rifampicin and isoniazid). We cannot draw a definitively conclusion that HLA-B*58:02 or HLA-DRB1*09:01 are specific to either isoniazid and/or rifampicin-related CADR. Larger studies are needed to determine if HLA genotypes are TB-drug specific.

HLA-B*58:02 is associated with rapid progression of HIV in a person who expresses the allele (Ngumbela et al. 2008). The HLA-B*58:02 noted in our cases and controls tolerant of the drugs might not be associated with CADR but could be a reflection of the HIV status and control in HIV-TB co-infected persons. Although our numbers were small there was no association between HIV infection and the presence of the HLA-B*58:02 in our study co-hort. HLA-B* 58:01 has been shown to be protective in HIV infected persons by reducing viral load replication and inducing cytotoxic T cell lymphocyte responses (Miura et al. 2009; O'Connell et al. 2009). Although present amongst the study and general population controls the numbers were too small to allow for meaningful analysis of a contribution of this effect on or results. A bigger study is needed to explore the association between HLA-B*58:02 and HLA-DRB1*09:01 in HIV-TB co-infected persons with severe CADR and relate it to HIV disease progression. This would establish more firmly whether HIV is a confounder in the HLA-B*58:02 allele CADR association.

The possible explanations for the large number of HIV infected individuals in our study population includes the high prevalence of HIV in the general South African population, higher rates of TB infection among HIV infected individuals and low social economic status (Department of Health Republic of South Africa 2014). We also postulate theoretically the presence of HLA-B* 58:02 vs HLA-B*58:01 may play a role in the progression of HIV predisposing them to TB.
Study limitations are as follows:

- The lack of a significant association between HLA genotype and CADR when cases were compared to our study controls could be explained by the small sample size. Alternatively other factors such as TB or viruses such as HIV or HHV6 present in both groups may be acting as confounders.
- Our population was not homogenous comprising patients of black and mixed descend.
- Due to the small study population and the rarity of the disease, we used only isoniazid and rifampicin associated CADR for HLA genotyping as they are the most important first line anti-tuberculosis drugs even though they are not the same calls of drug and do not share the same metabolism. A comparison of all first line anti-tuberculosis drugs for specific HLA associations in a larger study is needed.
- Our preliminary hypothesis was that HLA may present the drug to T cells to induce hypersensitivity reactions, and therefore, we checked the HLA association. The sample size of cases was too small, and the p value became non-significant after correction for multiple testing. An increased sample size of cases as well as the drug-tolerant controls is necessary to investigate whether the corrected p value is still significant.

In summary, HLA-B*58:02 and HLA-DRB1*09:01 may be associated with rifampicin and isoniazid-associated CADR. Alternately HLA-B*58:02 may be associated with HIV status rather than CADR. A sufficiently powered study is needed to confirm this association.

MATERIALS AND METHODS

Study participants

A case-control study was conducted in, Cape Town, South Africa. The cases were patients with previous tuberculosis-associated severe CADR who were re-challenged with first-line anti-tuberculosis drugs and subsequently developed re-challenge
reactions to either isoniazid and/or rifampicin. Two groups of controls were selected. Control group 1 (30 patients), were patients that tolerated first line anti-tuberculosis drugs, either isoniazid and rifampicin tolerant during re-challenge following severe CADR (12 patients Group 1a) or isoniazid and rifampicin tolerant throughout a course of treatment (18 patients Group 1b). Control group 2 comprised 200 black South Africans from the general population whose HLA allele frequencies had previously been published (Paximadis et al. 2012). This study was conducted for one year (December 2013-December 2014) but the cases and control group 1a were part of a larger study evaluating the best method for TB medication re-challenge/reintroduction after CADR. The Seventy four patients made up the cohort who were re-challenged prospectively over 8 years. The cases and controls which were recruited from this cohort to participate in our study according to protocol were 44. The remaining 30 who had all been re-challenged were not contactable or available for various reasons (9 dead, 5 refused to participate, 16 not reachable). Of the 44 recruited, 14 were rifampicin re-challenge positive cases, 7 were isoniazid re-challenge positive, 3 were pyrazinamide re-challenge positive, 2 were ethambutol re-challenge positive and 18 were full first line TB medication re-challenge negative controls. Some of the cases and controls recruited did not have blood samples taken for genotyping (5) while the rest (14) had failed genotyping. Finally genotyping data was available for 26 cases and control group 1a for analysis (Table S2 Figure 1). The control patients who experienced no ADRs to anti-tuberculosis first-line were consecutive cases of patients on TB treatment admitted to hospital for unrelated reasons (Group 1b). Cases and controls were recruited in a ratio of 1:2

Inclusion criteria of the study participants

Cases:

1. Participants willing and able to sign an informed consent
2. Adults who had serious CADR and had positive oral provocation test, patch test or skin prick test to anti-tuberculosis drugs with either rifampicin and/or isoniazid identified as the offending drugs
Controls:

1. Adult patients who had serious CADR but tolerated rifampicin and isoniazid after re-challenge
2. Adult patients who tolerated anti-tuberculosis drugs without developing any CADR

Exclusion criteria

1. Patients who are unwilling to sign an informed consent
2. Patients who had serious CADR to multiple anti-TB drugs

Management of participants before and during re-challenge

Cases

The anti-tuberculosis drugs were stopped when severe CADR to anti-TB drugs was suspected. Before re-challenge all patients were investigated to confirm active TB. Three second line anti-TB drugs (streptomycin, terizidone, ofloxacin, moxifloxacin, ethionamide, amikacin, kanamycin or para-amino-salicylic acid) to which the patient had not been previously exposed, were introduced to control active TB while waiting for the severe CADR and blood parameters to normalize. Depending on the sensitivities of the patient’s strain of TB, isoniazid followed by rifampicin, pyrazinamide and ethambutol were re-introduced consecutively and additively in accordance with a strict protocol. Once the patients had fully recovered the patients were re-challenged in hospital. A patch test was performed first, if negative, it was followed by a prick test and if this was also negative oral re-challenge was initiated. This re-challenge protocol was part of larger study which is still underway evaluating the best method to re-introduce medication after CADRs. For some cases only oral re-challenge was undertaken (Table S3) because of time constraints dictated by multiple co-morbidities and significantly ill patients. A positive re-challenge reaction following any of these re-challenge modalities lead to immediate withdrawal of the drug from the treatment regimen. Cases with a re-
challenge reaction to either isoniazid and/or rifampicin following any of the three re-challenges assessments constituted the cases (Figure 1). A re-challenge reaction was defined previously and fully described (Lehloenya et al. 2011). The patient demographics and CADR and re-challenge reactions are summarized in (Table S3 and S4).

**Controls**

Controls were consecutive patients who had tolerated rifampicin and isoniazid during the re-challenge process (12 patients, Group 1a) and consecutive patients who had been on TB treatment for at least 12 weeks without developing any ADR reaction but were admitted for unrelated medical problems (Group1b) (Figure 1). The causes of CADR in the control group 1a patients who had negative re-challenge to INH and Rif after CADR were due to drugs listed (Table S5).

**HLA genotyping**

Ten millilitres of a participant’s whole blood were collected in ethylenediaminetetraacetic acid (EDTA) tubes and stored at -80 degree Celsius within an hour of sample collection. Genomic DNA was isolated from the whole blood using the Gentra Puregene DNA purification kit (QIAGEN, Hilden, Germany). Each sample was typed for HLA-A, HLA-B, HLA-C, HLA-DRB1 alleles at high resolution by polymerase chain reaction with a Group Specific Sequencing Primers (GSSPs) typing method using the SeCore® HLA Sequence-Based Typing kits (Invitrogen by Life Technologies, Wisconsin, USA) according to the manufacturer’s protocols. Briefly, purified DNA was prepared to a working solution at 15-30 ng/μL in DNA hydration solution. For each amplification reaction, 50ng prepared DNA was combined 9.9 μl of Amp Mix with 0.1 μl of FastStart™ Taq DNA Polymerase. We confirmed the presence of PCR products (~1100 and ~1300bp at A locus, or ~950 and ~1400bp at B locus, respectively) by 2% agarose gel electrophoresis. The resulting product was treated with 2μl ExoSAP-IT™ to degrade the unincorporated primers and hydrolyze the free nucleotides. For each positive PCR reaction, we set up forward and reverse sequencing reactions for exon 2, 3 and 4 at A, B, C or DRB loci. After cycle sequencing, an ethanol precipitation with PPT buffer was performed to remove excess terminators. The HLA type results were determined by

**Ethics**

The study was conducted in accordance with ethical principles contained in the Helsinki declaration. The study was approved by the Human Research Ethics Committee of the University of Cape Town (HREC REF: 582/2012) (Appendix 1). Informed written consent (Appendix 2) was translated into isiXhosa and Afrikaans, the other two major languages in the catchment area. Informed written consents were obtained from all study participants. Participant’s details were collected from their hospital medical records and recorded in a clinical record form (Appendix 3). Anonymity was assured by allocating consecutive numbers to patients and recruited control patients.

**Statistical analysis**

This is a pilot hypothesis generating study. As such the issue of multiplicity was deliberately not taken into account. Prior to this study, there was no available data to guide any sample power calculations.

The data was analyzed using GraphPad Prism software. Comparisons of the frequencies of the HLA allele or carriers between the subgroups were performed using Fisher’s exact tests. As the pre-defined hypothesis based test was applied for the HLA association analysis, no correction of the p value for multiple testing was used in this study. Odds ratios (ORs) were calculated using Haldane’s modification, which added 0.5 to all cells to accommodate possible zero counts. The statistical significance was defined as a two-tailed p < 0.05.
CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGEMENT

We would like to thank our collaborators in Taiwan, Galderma and Dermatological Society of South Africa for funding the research. We would like to express our sincere gratitude to Sister Juliet Esterhuizen, all the patients together with the Dermatology team from Groote Schuur hospital
REFERENCES


Table 1: Demographic and clinical characteristics of 14 cases that developed a re-challenge reaction to rifampicin and/or isoniazid and 30 controls who tolerated rifampicin and/or isoniazid

<table>
<thead>
<tr>
<th></th>
<th>Cases; n=14</th>
<th>Controls; n=30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group 1a; n=12</td>
<td>Group 1b; n=18</td>
</tr>
<tr>
<td>Age(years), median [IQR]</td>
<td>32 (28-37)</td>
<td>36 (33-39)</td>
</tr>
<tr>
<td>Gender: n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8 (57%)</td>
<td>6 (50%)</td>
</tr>
<tr>
<td>Male</td>
<td>6 (43%)</td>
<td>6 (50%)</td>
</tr>
<tr>
<td>Race: n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>10 (71%)</td>
<td>8 (67%)</td>
</tr>
<tr>
<td>Mixed race</td>
<td>4 (29%)</td>
<td>4 (33%)</td>
</tr>
<tr>
<td>HIV status: n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>11 (79%)</td>
<td>12 (100%)</td>
</tr>
<tr>
<td>Negative</td>
<td>3 (21%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>CD4 count cells/mm³, median [IQR]</td>
<td>149 (74-329)</td>
<td>108 (39-141)</td>
</tr>
<tr>
<td>On ARVs</td>
<td>6 (43%)</td>
<td>5 (42%)</td>
</tr>
<tr>
<td>PREVIOUS TB: n</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>CADR to first-line TB treatment</td>
<td>14 (100%)</td>
<td>12 (100%)</td>
</tr>
<tr>
<td>Types of initial CADR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SJS</td>
<td>1 (7%)</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>TEN</td>
<td>0 (0%)</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>SJS/TEN overlap</td>
<td>0 (0%)</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>DRESS/DIHS</td>
<td>13 (93%)</td>
<td>7</td>
</tr>
<tr>
<td>Pseudo porphyria</td>
<td>0 (0%)</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0 (0%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>CADR to second-line TB treatment</td>
<td>3 (21%)</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Moxifloxacin/thionamide/amikacin</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

CDR = cutaneous adverse drug reaction; IQR = interquartile range; HIV = human immunodeficiency virus; TB = tuberculosis; ARVs = antiretroviral drugs; DRESS = drug rash with eosinophilia and systemic symptoms; SJS = Stevens Johnson syndrome; TEN = toxic epidermal necrolysis; SJS/TEN = Stevens Johnson syndrome and toxic epidermal necrolysis overlap; Na=not applicable.
## Table 2: The association between HLA-genotype and the HIV status

<table>
<thead>
<tr>
<th>SORT NO</th>
<th>HIV</th>
<th>CASE/CONTROL</th>
<th>CD4 count cells/mm³</th>
<th>HLA-A Allele 1</th>
<th>HLA-B Allele 1</th>
<th>HLA-B Allele 2</th>
<th>HLA-C Allele 1</th>
<th>HLA-C Allele 2</th>
<th>HLA-DRB Allele 1</th>
<th>HLA-DRB Allele 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>KS13</td>
<td>1</td>
<td>Case</td>
<td>58</td>
<td>*29:02</td>
<td>*66:01</td>
<td>*13:02</td>
<td>*58:02</td>
<td>*06:02</td>
<td>*03:01</td>
<td>*08:04</td>
</tr>
<tr>
<td>KS20</td>
<td>1</td>
<td>Case</td>
<td>329</td>
<td>*68:01</td>
<td>*68:02</td>
<td>*15:10</td>
<td>*82:02</td>
<td>*03:02</td>
<td>*03:04</td>
<td>*10:01</td>
</tr>
<tr>
<td>KS22</td>
<td>0</td>
<td>Case</td>
<td>30:09</td>
<td>*68:02</td>
<td>*44:03</td>
<td>*58:02</td>
<td>*16:01</td>
<td>*16:01/02</td>
<td>*13:02</td>
<td>*15:03</td>
</tr>
<tr>
<td>KS24</td>
<td>1</td>
<td>Case</td>
<td>320</td>
<td>*03:01</td>
<td>*30:02</td>
<td>FR</td>
<td>*04:01</td>
<td>*06:02</td>
<td>*01:02</td>
<td>*03:02</td>
</tr>
<tr>
<td>KS25</td>
<td>1</td>
<td>Case</td>
<td>80</td>
<td>*03:01</td>
<td>*30:01</td>
<td>*15:10</td>
<td>*58:02</td>
<td>*03:04</td>
<td>*06:02</td>
<td>*10:01</td>
</tr>
<tr>
<td>KS26</td>
<td>1</td>
<td>Case</td>
<td>233</td>
<td>*03:01</td>
<td>*23:01</td>
<td>*07:02</td>
<td>*58:02</td>
<td>*02:10</td>
<td>*06:02</td>
<td>*03:02</td>
</tr>
<tr>
<td>KS29</td>
<td>1</td>
<td>Case</td>
<td>457</td>
<td>*02:05</td>
<td>*30:02</td>
<td>*45:01</td>
<td>*58:01</td>
<td>*07:01</td>
<td>*16:01</td>
<td>*01:02</td>
</tr>
<tr>
<td>KS32</td>
<td>0</td>
<td>Case</td>
<td>145</td>
<td>*23:01</td>
<td>*30:04</td>
<td>*15:03</td>
<td>*58:02</td>
<td>*03:01</td>
<td>*08:04</td>
<td></td>
</tr>
<tr>
<td>KS35</td>
<td>1</td>
<td>Case</td>
<td>63</td>
<td>*30:01</td>
<td>*33:01</td>
<td>*42:01</td>
<td>*42:01</td>
<td>*17:01</td>
<td>*17:01</td>
<td>*03:02</td>
</tr>
<tr>
<td>KS37</td>
<td>1</td>
<td>Case</td>
<td>401</td>
<td>*24:02</td>
<td>*30:01</td>
<td>*13:02</td>
<td>*18:01</td>
<td>*05:01</td>
<td>*06:02</td>
<td>*03:01</td>
</tr>
<tr>
<td>KS38</td>
<td>0</td>
<td>Case</td>
<td>26:01</td>
<td>*32:01</td>
<td>*07:02</td>
<td>*27:05</td>
<td>*02:02</td>
<td>*02:10</td>
<td>*04:01</td>
<td>*09:01</td>
</tr>
<tr>
<td>KS44</td>
<td>1</td>
<td>Case</td>
<td>74</td>
<td>*42:01</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>*09:01</td>
<td>*13:01</td>
</tr>
<tr>
<td>KS72</td>
<td>1</td>
<td>Case</td>
<td>149</td>
<td>*15:10</td>
<td>*58:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>*04:03</td>
<td>*14:01/54</td>
</tr>
<tr>
<td>KS7</td>
<td>1</td>
<td>control 1a</td>
<td>24</td>
<td>*18:01</td>
<td>*42:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS8</td>
<td>1</td>
<td>control 1a</td>
<td>91</td>
<td>*42:01</td>
<td>*57:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS14</td>
<td>1</td>
<td>control 1a</td>
<td>22</td>
<td>*07:02</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS16</td>
<td>1</td>
<td>control 1a</td>
<td>168</td>
<td>*57:03</td>
<td>*58:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS19</td>
<td>1</td>
<td>control 1a</td>
<td>39</td>
<td>*35:01</td>
<td>*53:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS21</td>
<td>1</td>
<td>control 1a</td>
<td>b Unk</td>
<td>*08:01</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS23</td>
<td>1</td>
<td>control 1a</td>
<td>395</td>
<td>*07:05</td>
<td>*13:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS45</td>
<td>1</td>
<td>control 1a</td>
<td>b Unk</td>
<td>*15:01</td>
<td>*15:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS54</td>
<td>1</td>
<td>control 1a</td>
<td>44</td>
<td>*15:03</td>
<td>*27:05</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS57</td>
<td>1</td>
<td>control 1a</td>
<td>131</td>
<td>*15:01</td>
<td>*47:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS58</td>
<td>1</td>
<td>control 1a</td>
<td>125</td>
<td>*18:01</td>
<td>*44:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS66</td>
<td>1</td>
<td>control 1a</td>
<td>141</td>
<td>*57:02</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS1</td>
<td>0</td>
<td>control 1b</td>
<td>39</td>
<td>*07:02</td>
<td>*15:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS2</td>
<td>1</td>
<td>control 1b</td>
<td>5</td>
<td>*39:10</td>
<td>*42:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS9</td>
<td>1</td>
<td>control 1b</td>
<td>314</td>
<td>*15:10</td>
<td>*42:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS10</td>
<td>1</td>
<td>control 1b</td>
<td>323</td>
<td>*58:02</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS12</td>
<td>1</td>
<td>control 1b</td>
<td>101</td>
<td>*08:01</td>
<td>*13:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS17</td>
<td>1</td>
<td>control 1b</td>
<td>236</td>
<td>*42:01</td>
<td>*44:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS18</td>
<td>1</td>
<td>control 1b</td>
<td>333</td>
<td>*42:02</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS30</td>
<td>1</td>
<td>control 1b</td>
<td>124</td>
<td>*15:10</td>
<td>*42:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS31</td>
<td>0</td>
<td>control 1b</td>
<td>101</td>
<td>*15:10</td>
<td>*42:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS34</td>
<td>1</td>
<td>control 1b</td>
<td>76</td>
<td>*44:03</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS36</td>
<td>unk</td>
<td>control 1b</td>
<td>*13:02</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KS39</td>
<td>1</td>
<td>control 1b</td>
<td>274</td>
<td>*42:01</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS42</td>
<td>0</td>
<td>control 1b</td>
<td>720</td>
<td>*13:02</td>
<td>*15:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS43</td>
<td>0</td>
<td>control 1b</td>
<td>*15:10</td>
<td>*44:03</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KS53</td>
<td>1</td>
<td>control 1b</td>
<td>548</td>
<td>*42:01</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS55</td>
<td>0</td>
<td>control 1b</td>
<td>548</td>
<td>*45:01</td>
<td>*58:02</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS56</td>
<td>1</td>
<td>control 1b</td>
<td>300</td>
<td>*15:03</td>
<td>*27:05</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
<tr>
<td>KS74</td>
<td>1</td>
<td>control 1b</td>
<td>724</td>
<td>*07:02</td>
<td>*58:01</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td>FR</td>
<td></td>
</tr>
</tbody>
</table>

1=HIV infected; 0= HIV uninfected; unk=unknown; FR = failed typing
Table 3: Comparison of the HLA-B allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and the two control groups

<table>
<thead>
<tr>
<th>HLA</th>
<th>Cases n=13</th>
<th>Tuberculosis controls n=30</th>
<th>Population controls = 200</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>n</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>B*07:02</td>
<td>2</td>
<td>3</td>
<td>1.6(0.2 - 10.1)</td>
</tr>
<tr>
<td>B*07:05</td>
<td>0</td>
<td>1</td>
<td>0.1(0 - 860.4)</td>
</tr>
<tr>
<td>B*08:01</td>
<td>0</td>
<td>3</td>
<td>0(0 - 250.2)</td>
</tr>
<tr>
<td>B*13:02</td>
<td>2</td>
<td>4</td>
<td>1.2(0.2 - 6.8)</td>
</tr>
<tr>
<td>B*15:01</td>
<td>0</td>
<td>2</td>
<td>0(0 - 392)</td>
</tr>
<tr>
<td>B*15:03</td>
<td>1</td>
<td>5</td>
<td>0.4(0 - 4)</td>
</tr>
<tr>
<td>B*15:10</td>
<td>3</td>
<td>4</td>
<td>1.8(0.4 - 8.8)</td>
</tr>
<tr>
<td>B*18:01</td>
<td>1</td>
<td>2</td>
<td>1.2(0.1 - 13.4)</td>
</tr>
<tr>
<td>B*18:02</td>
<td>1</td>
<td>0</td>
<td>0(0 - 401350)</td>
</tr>
<tr>
<td>B*27:05</td>
<td>1</td>
<td>2</td>
<td>1.2(0.1 - 13.4)</td>
</tr>
<tr>
<td>B*35:01</td>
<td>0</td>
<td>1</td>
<td>0.1(0 - 860.4)</td>
</tr>
<tr>
<td>B*39:10</td>
<td>0</td>
<td>1</td>
<td>0.1(0 - 860.4)</td>
</tr>
<tr>
<td>B*42:01</td>
<td>3</td>
<td>8</td>
<td>0.8(0.2 - 3.5)</td>
</tr>
<tr>
<td>B*42:02</td>
<td>0</td>
<td>2</td>
<td>0(0 - 392)</td>
</tr>
<tr>
<td>B*44:02</td>
<td>1</td>
<td>0</td>
<td>50.3(0 - 401350)</td>
</tr>
<tr>
<td>B*44:03</td>
<td>1</td>
<td>4</td>
<td>0.6(0.1 - 5.3)</td>
</tr>
<tr>
<td>B*45:01</td>
<td>1</td>
<td>1</td>
<td>2.4(0.1 - 39.1)</td>
</tr>
<tr>
<td>B*47:01</td>
<td>0</td>
<td>1</td>
<td>0.1(0 - 860.4)</td>
</tr>
<tr>
<td>B*53:01</td>
<td>0</td>
<td>1</td>
<td>0.1(0 - 860.4)</td>
</tr>
<tr>
<td>B*57:02</td>
<td>0</td>
<td>1</td>
<td>0.1(0 - 860.4)</td>
</tr>
<tr>
<td>B*57:03</td>
<td>0</td>
<td>2</td>
<td>0.1(0 - 392)</td>
</tr>
<tr>
<td>B*58:01</td>
<td>2</td>
<td>2</td>
<td>0.1(0 - 392)</td>
</tr>
<tr>
<td>B*58:02</td>
<td>7</td>
<td>10</td>
<td>1.8(0.6 - 5.5)</td>
</tr>
</tbody>
</table>

13 cases out of 14 cases had successful HLA-B genotyping and 1 failed. Controls are: 30 patients that tolerated rifampicin and/or isoniazid) and 200 black South African from the general population. na: not applicable
Table 4: Comparison of the HLA-DRB1 allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and black South African from the general population

<table>
<thead>
<tr>
<th>HLA</th>
<th>N</th>
<th>n</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRB1*01:02</td>
<td>2</td>
<td>19</td>
<td>1.6 (0.3-7.07)</td>
<td>0.639</td>
</tr>
<tr>
<td>DRB1*03:01</td>
<td>3</td>
<td>30</td>
<td>1.5 (0.4-5.11)</td>
<td>0.466</td>
</tr>
<tr>
<td>DRB1*03:02</td>
<td>5</td>
<td>39</td>
<td>2.0 (0.7-5.62)</td>
<td>0.191</td>
</tr>
<tr>
<td>DRB1*04:01</td>
<td>2</td>
<td>10</td>
<td>2.9 (0.6-13.78)</td>
<td>0.182</td>
</tr>
<tr>
<td>DRB1*04:03</td>
<td>1</td>
<td>0</td>
<td>43.7 (1.7-1097.78)</td>
<td>0.065</td>
</tr>
<tr>
<td>DRB1*07:01</td>
<td>1</td>
<td>28</td>
<td>0.5 (0.1-3.7)</td>
<td>0.710</td>
</tr>
<tr>
<td>DRB1*08:04</td>
<td>2</td>
<td>17</td>
<td>1.8 (0.4-8.0)</td>
<td>0.357</td>
</tr>
<tr>
<td>DRB1*09:01</td>
<td>2</td>
<td>2</td>
<td>15.3 (2.1-113.1)</td>
<td>0.023</td>
</tr>
<tr>
<td>DRB1*10:01</td>
<td>2</td>
<td>10</td>
<td>2.9 (0.6-13.8)</td>
<td>0.182</td>
</tr>
<tr>
<td>DRB1*12:02</td>
<td>1</td>
<td>0</td>
<td>43.7 (1.7-1097.8)</td>
<td>0.065</td>
</tr>
<tr>
<td>DRB1*13:01</td>
<td>3</td>
<td>50</td>
<td>0.8 (0.2-2.9)</td>
<td>1.000</td>
</tr>
<tr>
<td>DRB1*13:02</td>
<td>1</td>
<td>23</td>
<td>0.6 (0.1-4.6)</td>
<td>1.000</td>
</tr>
<tr>
<td>DRB1*14:01</td>
<td>1</td>
<td>3</td>
<td>4.6 (0.5-44.9)</td>
<td>0.238</td>
</tr>
<tr>
<td>DRB1*15:03</td>
<td>2</td>
<td>34</td>
<td>0.8 (0.2-3.7)</td>
<td>1.000</td>
</tr>
<tr>
<td>HLA</td>
<td>Cases n=10</td>
<td>Population controls= 200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>--------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>n</td>
<td>OR (95% CI)</td>
<td>p value</td>
</tr>
<tr>
<td>C*02:02</td>
<td>1</td>
<td>36</td>
<td>0.5(0.1-4.0)</td>
<td>1.000</td>
</tr>
<tr>
<td>C*02:10</td>
<td>2</td>
<td>0</td>
<td><strong>888.8(0.1-6431264.5)</strong></td>
<td><strong>0.002</strong></td>
</tr>
<tr>
<td>C*03:02</td>
<td>1</td>
<td>6</td>
<td>3.5(0.4-30.2)</td>
<td>0.291</td>
</tr>
<tr>
<td>C*03:04</td>
<td>2</td>
<td>20</td>
<td>2.1(0.4-9.5)</td>
<td>0.282</td>
</tr>
<tr>
<td>C*04:01</td>
<td>1</td>
<td>48</td>
<td>0.4(0.1-3.0)</td>
<td>0.492</td>
</tr>
<tr>
<td>C*05:01</td>
<td>1</td>
<td>3</td>
<td>6.5(0.7-64.6)</td>
<td>0.178</td>
</tr>
<tr>
<td>C*06:02</td>
<td>5</td>
<td>60</td>
<td>1.9(0.7-5.4)</td>
<td>0.214</td>
</tr>
<tr>
<td>C*07:01</td>
<td>1</td>
<td>30</td>
<td>0.6(0.1-4.9)</td>
<td>1.000</td>
</tr>
<tr>
<td>C*16:01</td>
<td>2</td>
<td>26</td>
<td>1.6(0.3-7.1)</td>
<td>0.635</td>
</tr>
<tr>
<td>C*17:01</td>
<td>2</td>
<td>44</td>
<td>0.9(0.2-4.0)</td>
<td>1.000</td>
</tr>
<tr>
<td>C*18:02</td>
<td>1</td>
<td>13</td>
<td>1.5(0.2-12.4)</td>
<td>0.500</td>
</tr>
</tbody>
</table>
Table 6: Comparison of the HLA-A allele frequencies among the cases that developed a re-challenge reaction to rifampicin and/or isoniazid and black South African from the general population

<table>
<thead>
<tr>
<th>HLA</th>
<th>Cases n=11</th>
<th>Population controls= 200</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>A*02:05</td>
<td>3</td>
<td>27</td>
<td>2.2(0.6-7.8)</td>
<td>0.199</td>
</tr>
<tr>
<td>A*03:01</td>
<td>1</td>
<td>26</td>
<td>0.7(0.1-5.3)</td>
<td>1.000</td>
</tr>
<tr>
<td>A*23:01</td>
<td>2</td>
<td>32</td>
<td>1.2(0.3-5.1)</td>
<td>0.694</td>
</tr>
<tr>
<td>A*24:02</td>
<td>1</td>
<td>8</td>
<td>2.3(0.3-19.5)</td>
<td>0.385</td>
</tr>
<tr>
<td>A*26:01</td>
<td>1</td>
<td>3</td>
<td>5.9(0.6-58.2)</td>
<td>0.193</td>
</tr>
<tr>
<td>A*29:02</td>
<td>1</td>
<td>25</td>
<td>0.7(0.1-5.5)</td>
<td>1.000</td>
</tr>
<tr>
<td>A*30:01</td>
<td>3</td>
<td>40</td>
<td>1.4(0.4-5.0)</td>
<td>0.481</td>
</tr>
<tr>
<td>A*30:02</td>
<td>2</td>
<td>38</td>
<td>0.9(0.2-4.2)</td>
<td>1.000</td>
</tr>
<tr>
<td>A*30:04</td>
<td>1</td>
<td>7</td>
<td>2.6(0.3-22.0)</td>
<td>0.351</td>
</tr>
<tr>
<td>A*30:09</td>
<td>1</td>
<td>0</td>
<td>380.9(0.0-3063625.4)</td>
<td>0.052</td>
</tr>
<tr>
<td>A*32:01</td>
<td>1</td>
<td>5</td>
<td>3.6(0.4-32.1)</td>
<td>0.276</td>
</tr>
<tr>
<td>A*33:01</td>
<td>1</td>
<td>1</td>
<td>15.8(1.1-233.1)</td>
<td>0.102</td>
</tr>
<tr>
<td>A*66:01</td>
<td>1</td>
<td>3</td>
<td>5.9(0.6-58.2)</td>
<td>0.193</td>
</tr>
<tr>
<td>A*68:01</td>
<td>1</td>
<td>13</td>
<td>1.4(0.2-11.2)</td>
<td>0.533</td>
</tr>
<tr>
<td>A*68:02</td>
<td>2</td>
<td>34</td>
<td>1.1(0.2-4.8)</td>
<td>1.000</td>
</tr>
</tbody>
</table>
**Figure 1:** Summary of cases and two control groups of the study.

- **CASES**
  - 23 patients who developed re-challenge reactions to rifampicin (14) isoniazid (7) or both drugs (2)

- **CONTROL GROUP 1a**
  - 23 patients who had tolerated rifampicin and isoniazid during the re-challenge

- **CONTROL GROUP 1b**
  - 18 patients who had been on TB treatment for at least 12 weeks without developing ADRs

- **CONTROL GROUP 1**
  - TOLERANT of RIFAMPICIN and INH
  - 30 patients

- **CONTROL GROUP 2**
  - GENERAL BLACK POPULATION
  - 200 persons

- **74 patients with TB and severe TB-associated CADR re-challenged with first line anti-tuberculosis drugs**
  - 30 unavailable
  - 44 available

- **South Africans on first line anti-tuberculosis treatment**

- **black South Africans in the general population (Paximadis et al. 2012)**
Supplemental materials

Table S1: Association between CADR and modalities of re-challenge among the of 14 cases that developed a re-challenge reaction to rifampicin and/or isoniazid

<table>
<thead>
<tr>
<th>Mode of re-challenge</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIF patch testing reaction</td>
<td>3</td>
</tr>
<tr>
<td>INH oral re-challenge reaction</td>
<td>4</td>
</tr>
<tr>
<td>RIF oral re-challenge reaction</td>
<td>5</td>
</tr>
<tr>
<td>INH &amp; RIF oral re-challenge reaction</td>
<td>2</td>
</tr>
</tbody>
</table>

INH= isoniazid and RIF= rifampicin
INH & RIF: Had a reaction to isoniazid after normalized, was re-challenged with rifampicin and developed another reaction
Table S2: The distribution of the cases, controls and HLA genotyping

<table>
<thead>
<tr>
<th>Potential positive cases for inclusion</th>
<th>Total</th>
<th>Included in the study</th>
<th>Included in analysis</th>
<th>Excluded from analysis</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>*RIFAMPICIN</td>
<td>14</td>
<td>14</td>
<td>8</td>
<td>6</td>
<td>5 failed genotyping</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 blood not sent</td>
</tr>
<tr>
<td>*ISONIAZID</td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>1</td>
<td>1 failed genotyping</td>
</tr>
<tr>
<td>PYRAZINAMIDE</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>2 failed genotyping</td>
</tr>
<tr>
<td>ETHAMBUTOL</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2 failed genotyping</td>
</tr>
<tr>
<td>SUCCEFUL RHZE RECHALLENGE</td>
<td>18</td>
<td>18</td>
<td>11</td>
<td>7</td>
<td>3 blood not sent</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4 failed genotyping</td>
</tr>
<tr>
<td>TOTAL</td>
<td>44</td>
<td>44</td>
<td>26</td>
<td>18</td>
<td>18</td>
</tr>
</tbody>
</table>

2 cases positive to rifampicin re-challenge were also positive on isoniazid re-challenge.

RHZE=RIF INH, PZA, ETH treatment
Table S3: Re-challenge methods and outcome reactions in the cases (bold) and control group 1a

<table>
<thead>
<tr>
<th>Method used to induce re-challenge reaction and outcome</th>
<th>Re-challenge reaction features</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT</td>
<td>SPT</td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Yes</td>
<td>NU</td>
</tr>
<tr>
<td>Yes</td>
<td>ND</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Yes</td>
<td>NU</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
<td>ND</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Yes</td>
<td>NU</td>
</tr>
<tr>
<td>Yes</td>
<td>ND</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>NU</td>
<td>NU</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>9</td>
</tr>
</tbody>
</table>

PT=patch test; SPT skin prick test; oral= oral re-challenge; Yes=PT/SPT/oral re-challenge was done and there was a reaction; No= PT/SPT/oral re-challenge was done but there was no a reaction; ND = PT/SPT/oral re-challenge was not done at all; CADR=cutaneous adverse drug reaction; DRESS=Drug reaction with eosinophilia and systemic symptoms; RIF=rifampicin, INH=isoniazid, PZA=pyrazinamide; moxiflox=moxifloxacin, oflox=ofloxacin, ethion=ethionamide, ami=amikacin
Table S4: Blood parameters on admission CADR

<table>
<thead>
<tr>
<th>WCC</th>
<th>Eos</th>
<th>Max Eos</th>
<th>Lymphs</th>
<th>ALT</th>
<th>Max ALT</th>
<th>AST</th>
<th>Max AST</th>
<th>Tot bili</th>
<th>Conj bili</th>
<th>Urea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal range</td>
<td>4.0-10 × 10⁹/l</td>
<td>0.00-0.45× 10⁹/l</td>
<td>0.00-0.45× 10⁹/l</td>
<td>1.00-4.00× 10⁹/l</td>
<td>5-40U/l</td>
<td>5-40U/l</td>
<td>5-40U/l</td>
<td>0-21μmol/l</td>
<td>0-6μmol/l</td>
<td>2.6-7.0mmol/l</td>
</tr>
<tr>
<td>KS7</td>
<td>4.29</td>
<td>0.97</td>
<td>0.97</td>
<td>0.34</td>
<td>12</td>
<td>13</td>
<td>48</td>
<td>90</td>
<td>3</td>
<td>1.86</td>
</tr>
<tr>
<td>KS8</td>
<td>6.22</td>
<td>0.03</td>
<td>0.08</td>
<td>0.49</td>
<td>38</td>
<td>38</td>
<td>41</td>
<td>3</td>
<td>1</td>
<td>3.2</td>
</tr>
<tr>
<td>KS13</td>
<td>5.66</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>19</td>
<td>29</td>
<td>30</td>
<td>6</td>
<td>1</td>
<td>6.9</td>
</tr>
<tr>
<td>KS14</td>
<td>3.88</td>
<td>0.1</td>
<td>0.17</td>
<td>0.67</td>
<td>26</td>
<td>33</td>
<td>53</td>
<td>126</td>
<td>6</td>
<td>7.3</td>
</tr>
<tr>
<td>KS16</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
</tr>
<tr>
<td>KS19</td>
<td>4.9</td>
<td>0.11</td>
<td>0.11</td>
<td>0.4</td>
<td>22</td>
<td>24</td>
<td>36</td>
<td>2</td>
<td>3</td>
<td>3.3</td>
</tr>
<tr>
<td>KS20</td>
<td>6.52</td>
<td>0.05</td>
<td>0.05</td>
<td>0.65</td>
<td>179</td>
<td>179</td>
<td>79</td>
<td>79</td>
<td>19</td>
<td>3.7</td>
</tr>
<tr>
<td>KS21</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
<td>unk</td>
</tr>
<tr>
<td>KS22</td>
<td>4.58</td>
<td>0.9</td>
<td>0.9</td>
<td>0.94</td>
<td>27</td>
<td>27</td>
<td>41</td>
<td>41</td>
<td>2</td>
<td>1.1</td>
</tr>
<tr>
<td>KS23</td>
<td>3.53</td>
<td>0.14</td>
<td>0.25</td>
<td>ND</td>
<td>52</td>
<td>52</td>
<td>31</td>
<td>31</td>
<td>4</td>
<td>3.8</td>
</tr>
<tr>
<td>KS24</td>
<td>11.1</td>
<td>0.05</td>
<td>0.05</td>
<td>0.25</td>
<td>132</td>
<td>132</td>
<td>187</td>
<td>187</td>
<td>1</td>
<td>8.7</td>
</tr>
<tr>
<td>KS25</td>
<td>8.14</td>
<td>0.01</td>
<td>0.01</td>
<td>ND</td>
<td>58</td>
<td>329</td>
<td>106</td>
<td>821</td>
<td>8</td>
<td>3.5</td>
</tr>
<tr>
<td>KS26</td>
<td>8.07</td>
<td>0.08</td>
<td>0.08</td>
<td>0.67</td>
<td>53</td>
<td>53</td>
<td>32</td>
<td>57</td>
<td>4</td>
<td>5.5</td>
</tr>
<tr>
<td>KS29</td>
<td>5.99</td>
<td>0.2</td>
<td>0.2</td>
<td>2.48</td>
<td>54</td>
<td>54</td>
<td>80</td>
<td>80</td>
<td>1</td>
<td>2.2</td>
</tr>
<tr>
<td>KS32</td>
<td>4.71</td>
<td>0.16</td>
<td>0.25</td>
<td>1.77</td>
<td>19</td>
<td>19</td>
<td>30</td>
<td>46</td>
<td>5</td>
<td>1.95</td>
</tr>
<tr>
<td>KS33</td>
<td>7.16</td>
<td>0.04</td>
<td>0.22</td>
<td>ND</td>
<td>168</td>
<td>168</td>
<td>118</td>
<td>118</td>
<td>6</td>
<td>2.7</td>
</tr>
<tr>
<td>KS35</td>
<td>4.94</td>
<td>0.72</td>
<td>1.88</td>
<td>0.43</td>
<td>40</td>
<td>653</td>
<td>49</td>
<td>727</td>
<td>11</td>
<td>8.7</td>
</tr>
<tr>
<td>KS37</td>
<td>5.39</td>
<td>0.15</td>
<td>0.35</td>
<td>1.02</td>
<td>52</td>
<td>140</td>
<td>47</td>
<td>148</td>
<td>4</td>
<td>2.7</td>
</tr>
<tr>
<td>KS38</td>
<td>8.49</td>
<td>0.43</td>
<td>0.43</td>
<td>0.77</td>
<td>63</td>
<td>219</td>
<td>100</td>
<td>288</td>
<td>18</td>
<td>6.1</td>
</tr>
<tr>
<td>KS44</td>
<td>1.52</td>
<td>0.07</td>
<td>0.07</td>
<td>0.29</td>
<td>19</td>
<td>31</td>
<td>31</td>
<td>32</td>
<td>3</td>
<td>4.2</td>
</tr>
<tr>
<td>KS45</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>KS44</td>
<td>3.05</td>
<td>0.06</td>
<td>0.22</td>
<td>ND</td>
<td>13</td>
<td>33</td>
<td>35</td>
<td>83</td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>KS47</td>
<td>3.74</td>
<td>0.65</td>
<td>0.65</td>
<td>0.84</td>
<td>51</td>
<td>91</td>
<td>89</td>
<td>169</td>
<td>5</td>
<td>3.9</td>
</tr>
<tr>
<td>KS58</td>
<td>10.53</td>
<td>0.12</td>
<td>0.59</td>
<td>5.08</td>
<td>9</td>
<td>9</td>
<td>7</td>
<td>21</td>
<td>5</td>
<td>3.7</td>
</tr>
<tr>
<td>KS66</td>
<td>2.85</td>
<td>0.18</td>
<td>0.27</td>
<td>ND</td>
<td>25</td>
<td>47</td>
<td>57</td>
<td>59</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>KS72</td>
<td>4.43</td>
<td>0.12</td>
<td>0.22</td>
<td>1.18</td>
<td>16</td>
<td>16</td>
<td>38</td>
<td>41</td>
<td>5</td>
<td>2.6</td>
</tr>
</tbody>
</table>

WCC=white cell count; Eos= eosinophils; Lymphs= lymphocytes; ALT=aspartate transaminase; AST=alanine transaminase; Tot bili=total bilirubin; Conj bili=conjugated bilirubin; unk=unknown; nd=not done
Table S5: The causes of CADR in the control group 1a patients who had negative re-challenge to INH and Rif after CADR

<table>
<thead>
<tr>
<th>SORT #</th>
<th>BACTRIM</th>
<th>ARVS</th>
<th>ANTI TB 1&lt;sup&gt;st&lt;/sup&gt; line</th>
<th>ANTI TB 2&lt;sup&gt;nd&lt;/sup&gt; line</th>
<th>ANTIBIOTICS</th>
<th>OTHER MEDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>1#</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>1#</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>1#</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>0</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>19</td>
<td>1#</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>21</td>
<td>0</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>23</td>
<td>0</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>vit B complex</td>
</tr>
<tr>
<td>45</td>
<td>0</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>54</td>
<td>1#</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>57</td>
<td>1#</td>
<td>0</td>
<td>0</td>
<td>1 amikacin (moxifloxacin, ethionamide,)</td>
<td>0</td>
<td>Pyridoxine</td>
</tr>
<tr>
<td>58</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>66</td>
<td>0</td>
<td>0</td>
<td>PZA*</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Positive re-challenge
#Bactrim withdrawn – not re-challenged
+ARVs changed to exclude nevirapine and efavarence
Case 58: No cause for the drug reaction found and patient had full first line TB treatment successfully re-introduced.
APPENDICES

Appendix 1a: Ethics approval letter from the Faculty Research Ethics Committee
Appendix 1b: Annual Progress Report/Renewal
### Appendix 2a: English consent form

**UNIVERSITY OF CAPE TOWN**  
**FACTOR OF HEALTH SCIENCES**

**FACULTY OF HEALTH SCIENCES**  
**HUMAN RESEARCH ETHICS COMMITTEE**

**FHS017: Annual Progress Report/ Renewal**

**Record Reviews/Audits/Collection of Biological Specimens/Repositories/Databases/Registries**

<table>
<thead>
<tr>
<th>HREC reference only</th>
<th>(PAW053145777: HREC031358)</th>
</tr>
</thead>
</table>

**Thy serve as notification of annual approval, including any documentation described below.**

- **Approved** Annual progress report
- **Approved until next renewal date**
- **Not approved** See attached comments

- **Signature** Chairperson of the HREC
- **Date Signed** [Signature]

**Principal Investigator to complete the following:**

1. **Protocol Information**
   - **Date form submitted** 08/09/13
   - **HREC Ref Number** 982012
   - **Current HREC Approval was granted until** 15/06/2011
   - **Protocol title** GENOMICS STUDY OF ANTI-TUBERCULOSIS DRUGS INDUCED HYPERSENSITIVITY REACTIONS
   - **Principal Investigator** DR. MAAMOELE LOHELENE
   - **Department/Office** DERMATOLOGY, GROOTE SCHUUR HOSPITAL, 0299 HOMS HOSPITAL, CAPE TOWN 7925

2. **Protocol status (tick ✓)**
   - **Research-related activities are ongoing**
   - **Data collection is complete, data analysis only**

3. **Protocol summary**
   - **Total number of records or specimens collected, reviewed or stored since the original approval** 88
   - **Total number of records or specimens collected, reviewed or stored since last progress report** N/A
   - **Have any research-related outputs (e.g. publications, abstracts, conference presentations) resulted from this research?** Yes

4. **Signature**
   - **Signature of PI** [Signature]
   - **Date** 20/04/2012
   - **Signature of Supervisor** [Signature]
   - **Date** 20/04/2012

**[Note: Please complete the Data Form (FHS016) if the study is completed within the approval period.]**

---

**FHS017**

**Page 1 of 1**

(18 JUN 2011)

(For Baxter completion the Data Form (FHS016) if the study is completed within the approval period)
GENOMICS STUDY OF ANTI-TUBERCULOSIS DRUG-INDUCED HYPERSENSITIVITY REACTIONS

I, ________________, agree to take part in this research on my own free will. The reasons, benefits and the risks of the research have been explained to me in the language I understand by Doctor.

I have been told that the reason for this research is to find out which of my genes contributed to the reaction I had to my treatment for tuberculosis.

Two blood samples of 5ml each will be collected from me. One will be sent to a laboratory overseas that has the ability to do the tests and the other sample will be stored here in Cape Town for future studies related only to this research. The samples sent overseas will be destroyed immediately after the experiments. My expressed permission will be obtained for these future studies. I understand that the research may not benefit me directly, but may help others in the future including my own children or family.

The records of the research will be kept safely and only the team doing the research will be able to use it. The findings of the study may be published in scientific journals and meetings, but I will not be identified. I understand that I will not get any payment for the work related to the research.

Would you like to know the finding of the research

yes _ ____________

no _

If yes at the following address and telephone number: ________________ .

If you have any further questions you can contact Dr Shebe or Dr Lehloenya at 021 404 5269

Permission of this research was given on ____________ May, 2013 _______ by the Human Research Ethics Committee of the University of Cape Town. If you have any complaints about the conduct of this research please contact Professor Marc Blockman on Tel: 0214066492

I agree to take part of my own free will and I can stop at any time without having to give a reason for it.

__________________________                     _____________________________

Printed name of participant                             Signature, Mark, or Thumb Print

__________________________                     _____________________________

Investigator’s name (Print)                             Signature

Date __________________

__________________________                     _____________________________

Witness’s name (Print)               Signature

Date __________________

CONSENT TO OBTAIN A SPECIMEN FOR GENETIC TESTING

SAMPLE TYPE: BLOOD
GENETIC TESTING REQUESTED FOR:
Susceptibility to adverse reactions to TB drugs
The intended purpose of this test is predictive
1. I have been informed about the purpose of this genetic test.
2. I have received an explanation of the limitations of this genetic test.
2. Dr____________________ has discusses the benefits and risks of this genetic test with me.
4. I understand some genetic tests can involve possible medical, psychological or insurance issues of my
family
5. I have been informed how I will receive the results
6. I have been informed who may have access to my blood sample, and that any leftover sample may be
retained by researchers at the University of Cape Town.
7. I have been informed who may have access to my genetic test results, which is part of my confidential
medical records.
8. My questions have been answered to my satisfaction.
Permission of this research was given on _____29th May, 2013_______ by the Human
Research Ethics Committee of the University of Cape Town. If you have any complaints about the
conduct of this research please contact Professor Marc Blocman on Tel: 0214066492

I consent to have samples taken from genetic testing for the condition listed above and I am aware that I
can withdraw this consent at any time without having to give a reason for it

______________________________  ______________________________
Printed name of participant          Signature, Mark, or Thumb Print
______________________________  ______________________________
Investigator’s name (Print)          Signature
Date __________________________
______________________________  ______________________________
Witness’s name (Print)              Signature

Appendix 2b: IsiXhosa consent form
GENOMICS STUDY OF ANTI-TUBERCULOSIS DRUG-INDUCED HYPERSENSITIVITY REACTIONS

(lincukacha ngegenes ezichaphazelekayo ekulweni komzimba namachiza esifo semiphunga)

Mna ………………………………………………… Ndiyavuma ukuthata inxaxheba kolu phando ngaphandle kokugunyaziswa. Injogo,
inzuvo kunye namakhwininba zichaziwe nguGqirha………………………………………… esebenzisa ulwimi olucacileyo.

Ndixelelwе ukuba injongo zoluphando kukuзumа ukufumаna ukuba iigenes zam ziyachaphazelkekusini na ekulweni komzimba
wam namachiza esifo semiphungap.

Kuya kutathwa kum igazi elilinganiselwa kwisihlanu samamillitha (tisipuni) kabini kuphela. Elinye igazi liyakuthunyelwa kumaziko
okuhlola igazi akumazwe angapheshheyeya kolwandle, ukuze lihlolwe khona. Elinye igazi liyakugcinwa kumaziko okuhlola igazi
alapha eKapa ukuze lihlolwe kwixesha elizayo lihlolwe kwaxolu phando kuphela. Igazi elithunyelwe kumazwe angapheshheyeya liya
kulahlwa kwangoko kwakugqitywa uhlolo. Imvume yam iyakuphinde icelwe xa kufuneka olunye uhlolo kwixesha elizayo. Ndiyazi
ukuba kungenzeka mna ngokwam ndingazuzi nto kolu phando koko kuzuze abanye abantu abanye abantu ekuphika kubekukathwa
kosapho lwam.

Amacwecwe oluphando ayakugcinwa eluvalelwе ukuze afumaneke kuphela kubantu abenza olu phando kuphela. Iziphumo
zophando kungenzeka zipapashwe emaphepheni enzululwе kunye nasezintlanganisweni kodwa igama lam alisayi
kungqanyaniswa nezo ziphuma. Ndiyazi andisayi kuhlawula ngokuthatha inxaxheba kolu phando.

Ungathanda na ukuzazi iziphumo zophando? Ewe noba hayi

Ukuba uthi ewe nceda ubhale idilesi nenombolo yakho
yemfonomfono………………………………………………………………………………………………………………………………………
…………………………………………

Ukuba unemibuzo ngophando tsalela umnxeba uGqirha Shebe okanye uGqirha Lehloenya ku 021 404 5269.

Imvume yokwenza uphando ifumaneke ngomhla ka………………………………………inikezwa licandelo leHuman Research ethics committee kwi
Univesiti yaseKapa (University of Cape town). Ukuba zikhona izikhulazalo mayela nolu phando nceda utsalele umnxeba uProfesa
Marc Blockman ku 021 406 6492.Ndivumile ukuthathwa inxaxheba kolu phando kwaye ndiyazi ndingasirhoxisa esi sivumelwano
nangaliphi ixesha ngaphandle kokunika izizathu.

Igama lophandwayo utyikityo, uphawu okanye umnwe
………………………………………………………………………………………………………………………………………………

Igama lomphandi utyikityo
………………………………………………………………………………………………………………………………………………

Umhla………………………………………………………………………………………………………………………………………………

Igama lengqina utyikityo
………………………………………………………………………………………………………………………………………………

IMVUME YOKUNIKEZELA NGEGAZI KUHLONGO LWEGENES

74
Uhlobo lwesample: Igazi

Uhlobo lohlolo lwegenes elizakwenziwa:

Kungaba zikhona na izintsolo zokuthi umzimba wamahlule wase esimo esimo semiphungu.

1. Ndidlele ngeenjongo zokuhlolo lwegenes

2. Ndichazelwe ngamakhwiniba anxulumene nolu hlolo lwegenes

3. UGqhirha……………………………….. ndichazele ngendzuza nokungahle kungahabi kakuhle kolu hlolo lwegenes.

4. Niyazi ukuba ukuhlovi kwe genes zamu kungahle kudale ingxakile emzimbeni, egqondeni nomshwalense (insurance) kusapho lwam.

5. Ndichazelwe ukuba ziyakufumaneka njani iziphumo zophando

6. Ndichazelwe ukuba ngubani oyakukwazi ukufumana igazi endinikezele ngalo, nokuba igazi eliseleyo liyakugcinwa ngabaphandi kwUnivesiti yase Kapa (University of cape Town)

7. Ndichazelwe ukuba ngubani oyakufumana iziphumo zophando ezivyeningxenye ezeemfihlo eziqualthwe kwesingle kwesizankelo zonyango.

8. Imibuzo yam iphendulwe ngokwanelisayo

Imvume yokwenza uphando ifumane nehlolo ka………………………….. inikezu licandelo leHuman Research ethics committee kwi Univesiti yaseKapa (University of cape Town) Ukuba zikhona izikhala zokufumana mayela nolu phando nceda utsalele umnxeba uProfesa Marc Blockman ku 021 406 6492

Ndivumile ukuba kuthathwa igazi kuhlolo lwegenes phantsi kwezi meko zingenthwa kwaye ndiyazi ndingaehredoza esi sivumelwano nangaliphi ikesha ngaphandle kokunikwa izithu.

Igama lophandwayo uyikityo, uphawo okanye umnwe

…………………………………………………………………………………………………………………………

Igama lomphandi uyikityo

…………………………………………………………………………………………………………………………

Umhla………………………………

Igama lengqina uyikityo

…………………………………………………………………………………………………………………………

Umhla………………………………

Appendix 2c: Afrikaans consent form
TOESTEMMINGSVORM

GENOMIKA VAN ANTI-TUBERKULOSE MIDDEL GEINDUSEERDE HIPERSENSITIWITEITS REAKSIES

Ek, ____________ stem in om deel te neem aan hierdie navorsing uit vrye wil. Die redes, voordele en risikos hieraan verbonde is aan my meegedeel deur dokter _______ in n taal wat ek verstaan.

Ek is meegedeel dat die rede vir hierdie navorsing is om te bepaal of my gene bygedra het tot die reaskie wat ek agv my anti-TB medikasie gehad het.

Twee bloed monsters van 5ml elk sal van my geneem word. Een sal na n laboratorium in die buiteland gestuur word wat oor die nodige toetse beskik en die ander monster sal in Kaapstad geberg word vir moontlike verdere toetse wat slegs met hierdie navorsing verband sal hou. Eersgenoemde monster sal vernietig word sodra die toetse afgehandel is. My toestemming sal verkry word alvorens verdere toetse op die ander monster verrig word. Ek verstaan dat die navorsing my nie direk sal bevoordeel nie, maar dat dit vir andere tot voordeel mag wees in die toekoms, insluitende my kinders en familie.

Die rekords van die navorsing sal veilig bewaar word en slegs die persone wie die navorsing gedaan het sal toegang daartoe hê. Die resultate van die navorsing mag gepubliseer word in wetenskaplike jouerne en by wetenskaplike vergaderings voorgedra word, maar ek sal nie geidentifiseer word nie. Ek verstaan dat ek nie vir die werk verbonde aan die navorsing betaal sal word nie.

Wil u ingelig word aangaande die bevindinge van die navorsing?    Ja   nee

Indien wel, wat is u adres en telefoon nommer? ______________________________

Indien u enige verdere vrae het kan u drs Shebe of Lehloenya kontak by 021 404 5269

Toestemming vir hierdie navorsing is gegee op ____________ deur die Menslike Navorsings Etiese Komitee van Kaapstad. Indien u enige klagtes aangaande die uitvoering van die navorsing het kontak asb Prof Marc Blockman by 021 406 6492.

Ek stem in om deel te neem uit vrye wil en kan ter enige tyd onttrek sonder om n rede daarvoor te verskaf.

Geskrewe naam van deelnemer: ____________________________
Handtekening of duim vingerafdruk

Ondersoeker se naam (skryf) ____________________________
Handtekening

Datum________________________

Getuie se naam (skryf) ____________________________
Handtekening

Datum________________________
TOESTEMMING VIR DIE VERKRYGING VAN N MONSTER VIR GENETIESE TOETSE

MONSTER TIPE: BLOED

GENETIESE TOETS AANGEVRA VIR:

Vatbaarheid vir newe effekte van TB medikasie
Die veronderstelde doelstelling van die toets is voorspellend.

1. Ek is ingelig aangaande die doelstelling van die genetiese toets.
2. Aan my is die tekortkominge van die toets verduidelik
3. Dr. _____ het met my die voordele en risikos van die genetiese toets bespreek.
4. Ek verstaan dat party genetiese toetse moontlike mediese, psigologiese of versekerings implikasies vir my en my familie kan inhou.
5. Aan my is meegedeel hoe ek die resultate kan bekom.
6. Aan my is meegedeel wie toegang tot my bloed monster het en dat wat daarvan oor is deur die navorsers van die Universiteit van Kaapstad gehou kan word.
7. Aan my is meegedeel wie toegang het tot my genetiese toets resultaat en dat dit deel uitmaak van my konfidesiele mediese rekort.
8. My vrae is beantwoord na my bevrediging.

Toestemming vir die navorsing was gegee op ____________ deur die Menslike Navorsings Ethise Komitee van die Universiteit van Kaapstad. Indien ek enige klagtes aangaande die uitvoering van die navorsing het kan ek Prof Marc Blockman kontak by 021 404 6492. Ek gee toestemming dat monsters van my geneem mag word vir genetiese toetse vir die toestand vermeld hierbo en ek is bewus dat ek hierdie toestemming ter enige tyd kan onttrek sonder om n rede daarvoor te verskaf.

Geskrewe naam van deelnemer: ____________________________  Handtekening of duim vingerafdruk

Ondersoeker se naam (skryf) ____________________________  Handtekening

Datum ____________________________  Datum ____________________________

Getuie se naam (skryf) ____________________________  Handtekening
Appendix 3: Clinical research form

A. Patient Demographics

A1: Surname: ____________________________________________

A2: Name ____________________________________________

A3: Folder No: ________________________________

A4: Date of birth: _____________________

A5: Sex: Male (1) Female (2)

A6: Ethnicity: Asian Yes (1) No (0) Black Yes (1) No (0) Coloured Yes (1) No (0) Indian Yes (1) No (0) White Yes (1) No (0)

Other capture text ________________________________

B: Comorbidities:

Hypertension Yes (1) No (0) Diabetic (Yes) No (0) Epilepsy (Yes) No (0)

Others capture text ____________________________________________

C: HIV status:

C1: HIV status known Yes (1) No (0)

C2: HIV infected Yes (1) No (0)

C3: CD4 count known: Yes (1) No (0)

C4: If known value of CD4 count: ___________cells/mm$^3$

C5: On HAART Yes (1) No (0)

D: Previous TB history

D1: Yes (1) No (0)

D2: Date of diagnosis ________________________________

D3: How was the TB diagnosed Sputum Yes (1) No (0) CXR Yes (1) No (0) Abd USS Yes (1) No (0) FNAB Yes (1) No (0) CSF Yes (1) No (0)

Other capture text ________________________________

D4: Sensitivity testing Yes (1) No (0)

D5: If Yes, Was it MDR Yes (1) No (0) Monoresistance Yes (1) No (0) Nonresistance Yes (1) No (0)
E: Previous completion Tb treatment

E1: Yes (1) No (0)

E2: If yes, how long was the TB treatment _________________________?

E3: If No, how long was the TB treatment _________________________?

F: ADR in previous TB treatment? Yes (1) No (0)

F1: Specify type of drug reaction

Stevens Johnson syndrome (SJS) Yes (1) No (0) Toxic epidermal necrolysis (TEN) Yes (1) No (0) SJS/TEN overlap Yes (1) No (0)

Drug hypersensitivity syndrome (DHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS) Yes (1) No (0)

Lichenoid drug reaction Yes (1) No (0) Photo induced drug reaction Yes (1) No (0)

Vasculitis Yes (1) No (0) AGEP Yes (1) No (0) Angioedema Yes (1) No (0)

Other (capture text)

G: Previous causative TB drugs known:

G1: Yes (1) No (0)

G2: If yes specify drug(s):

Rifampicin Yes (1) No (0) Isoniazid Yes (1) No (0) Pyrazinamide Yes (1) No (0) Ethambutol Yes (1) No (0) streptomycin Yes (1) No (0)

Ethionamide Yes (1) No (0) Ofloxacin Yes (1) No (0) Ciprofloxacin Yes (1) No (0) Azithromycin Yes (1) No (0) Amikacin Yes (1) No (0)
Thiacetazone: Yes (1) No (0)
Clofazimine: Yes (1) No (0)
Clarithromycin

Yes (1) No (0)
Kanamycin: Yes (1) No (0)
Terizidone: Yes (1) No (0)
PAS: Yes (1) No (0)

(1) No (0)
Cycloserine: Yes (1) No (0)
Rifabutin: Yes (1) No (0)

Other (capture text) ________________________________

H: Previous re-challenge of the TB medication:

Yes (1) No (0)

H1: If Yes, Date of Re-challenge ____________________________

H2: Date of completion of re-challenge ______________________

H3: If No, Reasons capture text ______________________________

I: Outcome of previous re-challenge

I1: Successful re-challenge with the patient on at least 4 anti Tb drugs

Yes (1) No (0)

I2: If yes, specify anti Tb drugs

Rifampicin: Yes (1) No (0) Isoniazid: Yes (1) No (0) Pyrazinamide: Yes (1) No
(0) Ethambutol: Yes (1) No (0) streptomycin: Yes (1) No (0)
Ethionamide: Yes (1) No (0) Ofloxacin: Yes (1) No (0) Ciprofloxacin: Yes (1) No
(0) Azithromycin: Yes (1) No (0) amikacin: Yes (1) No (0)
Thiacetazone: Yes (1) No (0) Clofazimine: Yes (1) No (0) Clarithromycin

Yes (1) No (0) kanamycin: Yes (1) No (0) Terizidone: Yes (1) No (0) PAS: Yes
(1) No (0)
Cycloserine: Yes (1) No (0) rifabutin: Yes (1) No (0)

Other (capture text) ________________________________

I3: Date of discharge______________________________________

I4: Completed treatment: Yes (1) No (0)
I5: If yes, how long_______________________________________

I6: If No, reason capture text________________________________

J: Date of current TB diagnosis  ______________________________________________

J1: How was the TB diagnosed Sputum Yes (1) No (0)  CXR Yes (1) No (0)
    Abd USS Yes (1) No (0)  FNAB Yes (1) No (0) CSF Yes (1) No (0) Other capture text
    __________________________________________________________________________

J2: Sensitivity testing Yes (1) No (0)

J3: If Yes, Was it MDR Yes (1) No (0) Monoresistance Yes (1)  No (0)
    Nonresistance Yes (1) No (0)

K: History of developing an IRIS

K1: Yes (1) No (0)

K2: If yes, specify capture text         ________________________________________________________

L: History of ADRS with current TB treatment

L1: Yes (1) No (0)

L2: Date of the first symptom of ADR ______________________________________________

L3: Symptoms: Nausea Yes (1) No (0)  Vomiting Yes (1) No (0)  Itch Yes (1) No (0)
    General pain Yes (1) No (0)  Sore throat Yes (1) No (0)  Sore eyes Yes (1) No (0)
    Erythema Yes (1) No (0)  Headache Yes (1) No (0)  Swelling Yes (1) No (0)  Rigors
    Yes (1) No (0)  Muscle pain Yes (1) No (0)  Abdominal pain Yes (1) No (0)
    Diarrhea Yes (1) No (0)  Palpitation Yes (1) No (0)  Fever Yes (1) No (0)
    Others capture text      _______________________________________________________________________

L4: History of taking medication 8 weeks before the reaction Yes (1) No (0)

L5: If Yes, Bactrim Yes (1) No (0)  ARV’S Yes (1) No (0)  anti TB Yes (1) No (0)
Antibiotics  Yes (1) No (0) others capture text

L6: Date of admission

L7: Date of stopping the medication

L8: Blood results on admission

EOS _______  LYMPHOCTE _______ ALT _______  AST _______
LIPASE _______  WCC _______  HB _______  TOT BILI _______
CONJ BILI _______  PLT _______ UREA _______
CREATININE _______  HEP A _______  HEP B _______
HEP C _______  EBV _______  VZV _______  HSV _______ -
HHV6 _______  HHV7 _______  TOXO _______

L9: Type of current ADR

Stevens Johnson syndrome (SJS)  Yes (1) No (0) Toxic epidermal necrolysis (TEN)  Yes (1) No (0)  SJS/TEN overlap  Yes (1) No (0)
Drug hypersensitivity syndrome (DHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS) Yes (1) No (0)
Lichenoid drug reaction  Yes (1) No (0)  Photo induced drug reaction  Yes (1) No (0)
Fixed drug eruption Yes (1) No (0)
Vasculitis  Yes (1) No (0)  AGEP  Yes (1) No (0)  Angioedema
Yes (1) No (0)  Morbilliform/exanthematous Yes (1) No (0)
Other (capture text)

M: Current causative TB drugs known:

M1: Yes (1)  No (0)
M2: If yes specify drug(s):

- Rifampicin Yes (1) No (0)
- Isoniazid Yes (1) No (0)
- Pyrazinamide Yes (1) No (0)
- Ethambutol Yes (1) No (0)
- streptomycin Yes (1) No (0)
- Ethionamide Yes (1) No (0)
- Ofloxacin Yes (1) No (0)
- Ciprofloxacin Yes (1) No (0)
- Azithromycin Yes (1) No (0)
- Amikacin Yes (1) No (0)
- Thiacetazone Yes (1) No (0)
- Clofazimine Yes (1) No (0)
- Clarithromycin Yes (1) No (0)
- kanamycin Yes (1) No (0)
- Terizidone Yes (1) No (0)
- PAS Yes (1) No (0)
- Cycloserine Yes (1) No (0)
- Rifabutin Yes (1) No (0)

Other (capture text) ___________________________________

M3: History of taking backbone drugs Yes (1) No (0)

M4: Duration of backbone drugs _____________________________

N: Re-challenge of TB medication

N1: Yes (1) No (0)

N2: Date of re-challenge _____________________________

N3: Successful re-challenge with the patient on at least anti TB drugs

Yes (1) N0 (0)

N4: If yes, specify anti Tb drugs

- Rifampicin Yes (1) No (0)
- Isoniazid Yes (1) No (0)
- Pyrazinamide Yes (1) No (0)
- Ethambutol Yes (1) No (0)
- streptomycin Yes (1) No (0)
- Ethionamide Yes (1) No (0)
- Ofloxacin Yes (1) No (0)
- Ciprofloxacin Yes (1) No (0)
- Azithromycin Yes (1) No (0)
- Amikacin Yes (1) No (0)
- Thiacetazone Yes (1) No (0)
- Clofazimine Yes (1) No (0)
- Clarithromycin Yes (1) No (0)
- kanamycin Yes (1) No (0)
- Terizidone Yes (1) No (0)
- PAS Yes (1) No (0)
- Cycloserine Yes (1) No (0)
- Rifabutin Yes (1) No (0)

Other (capture text) _____________________________
**N5:** If No, History of ADRS

**N6:** Yes (1) No (0)

**N7:** Symptoms and signs of the re-challenge reactions

Nausea Yes (1) No (0)  Vomiting Yes (1) No (0)  Itch Yes (1) No (0)

General pain Yes (1) No (0)  Sore throat Yes (1) No (0)  Sore eyes Yes (1) No (0)

Erythema Yes (1) No (0)  Headache Yes (1) No (0)  Swelling Yes (1) No (0)

Rigors Yes (1) No (0)  Muscle pain Yes (1) No (0)  Abdominal pain Yes (1) No (0)

Diarrhea Yes (1) No (0)  Palpitation Yes (1) No (0)  Fever Yes (1) No (0)  Others  

**N8:** Types of the drug reactions on re-challenge

Stevens Johnson syndrome (SJS)  Yes (1) No (0)  Toxic epidermal necrolysis (TEN)  Yes (1) No (0)  SJS/TEN overlap  Yes (1) No (0)

Drug hypersensitivity syndrome (DHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS) Yes (1) No (0)

Lichenoid drug reaction  Yes (1) No (0)  Photoinduced drug reaction  Yes (1) No (0)

Vasculitis  Yes (1) No (0)  AGEP  Yes (1) No (0)  Angioedema

Yes (1) No (0)  Morbilliform/exanthematous Yes (1) No (0)

**N9:** Causative drug known yes (1) no (0)

**N10:** Specify causative drugs on re challenge
Rifampicin Yes (1) No (0) Isoniazid Yes (1) No (0) Pyrazinamide Yes (1) No (0) Ethambutol Yes (1) No (0) streptomycin Yes (1) No (0) Ethionamide Yes (1) No (0) Ofloxacin Yes (1) No (0) Ciprofloxacin Yes (1) No (0) Azithromycin Yes (1) No (0) Amikacin Yes (1) No (0) Thiacetazone Yes (1) No (0) Clofazimine Yes (1) No (0) Clarithromycin Yes (1) No (0) kanamycin Yes (1) No (0) Terizidone Yes (1) No (0) PAS Yes (1) No (0) Cycloserine Yes (1) No (0) Rifabutin Yes (1) No (0)

Other (capture text) ________________________________

O: Duration before normalization after re challenge ADRS _______________

P1: Last date of re challenge ________________________________

P2: Specify anti Tb drugs the patient was discharge with

Rifampicin Yes (1) No (0) Isoniazid Yes (1) No (0) Pyrazinamide Yes (1) No Ethambutol Yes (1) No (0) streptomycin Yes (1) No (0) Ethionamide Yes (1) No (0) Ofloxacin Yes (1) No (0) Ciprofloxacin Yes (1) No (0) Azithromycin Yes (1) No (0) Amikacin Yes (1) No (0) Thiacetazone Yes (1) No (0) Clofazimine Yes (1) No (0) Clarithromycin Yes (1) No (0) kanamycin Yes (1) No (0) Terizidone Yes (1) No (0) PAS Yes (1) No (0) Cycloserine Yes (1) No (0) Rifabutin Yes (1) No (0)

Other (capture text) ________________________________

R: Final outcome

R1: Completed treatment Yes (1) No (0)

R2: If Yes, how long ________________________________

R3: If No,

R3:1: still on medications Yes (1) No (0) and for how long ________________________________
Appendix 4: Instructions to authors

INSTRUCTIONS TO AUTHORS

Aims & Scope | Article Types | Manuscript Submission | Manuscript Preparation | Registering and Reporting Clinical Trials | English Language Editing | Publication Charges | Accepted Article Preview (AAP) | Advance Online Publication | Proofs | Offprints |

Aims and Scope

The Journal of Investigative Dermatology (JID) publishes reports describing original research on all aspects of cutaneous biology and skin disease. Topics include biochemistry, biophysics, carcinogenesis, cell regulation, development, skin structure, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, physiology, pharmacology, photobiology, percutaneous absorption, clinical research, epidemiology and other population-based research.

Case reports or case series, unless they provide new biologic insights, are rarely appropriate for the Journal.

Mutation reports of mutations in known genes with no new mechanistic data will not be considered.
Original Articles, Review Articles, and Letters to the Editor are standard features. Perspectives and Commentaries are invited by the Editorial Board. Online features now under development seek to make JID content more relevant and accessible to trainees and clinician-educators.

Reports that primarily or exclusively concern a methodology, with the data documenting utility or feasibility, rather than providing new biologic insights, are discouraged, although exceptions to our policy of rejection may occasionally be made. Submissions reporting new methods in combination with mechanistic insights into the problem being investigated are, in contrast, most welcome.

**Article Types**

**Original Articles**

Original articles should not exceed 3,500 words and 6 figures or tables - not to exceed 7 printed journal pages. (For details on word and figure limits, see sections B and C below).

Original articles should be organized as follows: Title page, Abstract, Introduction, Results, Discussion, Materials & Methods, Conflict of Interest, Acknowledgments, References, Tables, Figure Legends, Supplementary Material.

**Review Articles**

A review article is expected to be comprehensive, scholarly, and balanced, presenting an expert curation of the literature in the topic of interest. Reviews are limited to: 100-word abstract; 3,000-word text, excluding references; and 2 figures. Authors are encouraged to consult the Editor before submitting a review for consideration.

**Letters to the Editor**

Letters to the Editor may report original data or discuss published articles. Letters are not to exceed 1,000 words and 2 figures or tables, and 15 references - not to exceed 3 printed journal pages. (For details on word and figure limits, see sections B and C below). Letters should not have an abstract. The Editor may solicit a response from the authors if a letter refers to an article published in JID. Letters that report original data will be fully peer-reviewed. All Letters to the Editor are subject to editing and possible abridgment.

**Manuscript Submission**
**JID** requires electronic submission of manuscripts. Detailed instructions are at our [Manuscript submission website](#). For assistance with the site, contact ScholarOne Manuscripts at +1 434-964-4100. For questions regarding your submission, contact the Editorial Office at +1 919-932-0140.

Complete submissions contain all items below, and submissions are dated according to receipt of all items. No editorial decision will be communicated to the authors until the submission is complete. Authors are encouraged to read **JID's Editorial Policies** before submitting their work.

All Submissions MUST Include:

- Cover letter stating:
  1. The data in the manuscript is original and the manuscript is not under consideration elsewhere;
  2. None of the manuscript contents have been previously published except in abstract form;
  3. All authors have read and approved all versions of the manuscript, its content, and its submission to the **JID**;
  4. The authors should state their willingness to pay page charges ($150/page, inclusive of color, for articles accepted after January 1, 2013), should the manuscript be accepted for publication;
  5. If the submission contains supplemental files, the authors should state their willingness to pay online fees ($125/file). This is payable at proof stage;
  6. The corresponding author's address, telephone, fax, email (email address required).

- License to Publish, signed by the corresponding author.
- Declaration of Conflict of Interest, signed by all authors.
- Manuscript Submission Fee of $50 (payable at time of submission)

---

**Manuscript Preparation**

**A. General**

The manuscript should be double-spaced throughout with wide (1" or larger) margins. Set your word processing software to 8.5 x 11 inch paper. Number pages consecutively (with the title page as page 1). Begin a new page for reference lists, tables, and figure legends. The file should use the wrap-around end-of-line feature, e.g., returns at the end of paragraphs only. Place two returns after every element, such as title, headings, paragraphs, figure and table callouts. The paper should be concise, economical of references, figures and tables, and formatted as described below. Reports of investigative studies should be organized as follows, within the stated word limits: Title page, Abstract, Introduction, Results, Discussion, Materials & Methods, Conflict of Interest, Acknowledgments, References, Tables, Figure Legends, Supplementary Material.
Manuscripts that do not conform to these specifications will be returned to the authors for correction prior to review.

B. Word Limits

Word limits will be instituted for all manuscripts accepted after January 1, 2010.

- Original articles should not exceed 3,500 words and 6 figures or tables—not to exceed 7 printed journal pages.
- Letters to the Editor should not exceed 1,000 words, 2 figures or tables, and 15 references—not to exceed 3 printed pages.
- Word counts include text only; the abstract, references, figure legends, tables, and supplemental data are excluded (note that figure legends are limited to 125 words each, and 500 words of article text may be exchanged for 1 figure or vice versa).
- There may be exceptions, which will be handled at the discretion of the Editor.
- Submissions that do not comply with these guidelines will be returned to authors for revision.

C. Figure/Table Size Limits

Beginning January 1, 2013, illustrative elements (figure/tables) are limited to ¼ page each (approx 87.5 mm x 115 mm). Authors may supply fewer, larger elements (i.e., for an original article three ½-page figures may be presented rather than six 1/4-page figures — or any combination that results in no more than 1 ½ pages of figures and tables). In addition, 500 words of text may be substituted for one figure, or vice versa. Submissions that do not comply with these specifications will be returned to the authors for correction prior to review.

D. Title

The title page should include the following:

- Brief, informative title of 120 characters or less (brand names may not be used in the title)
- Authors' full names, ORCID (if any), departments, and institutions (indicate affiliations numerically with numbers placed after authors' names and before the institutions);
  NOTE: all authors’ emails are required by our electronic submission system. Have these ready at the time of submission.
- City, state and country in which the work was done
- Corresponding author's address, telephone, fax and email (email address required)
• Short title of 45 characters or less, including spaces
• Abbreviations used (see item Q below for detail on abbreviations)

E. Abstract

• Do not exceed 200 words
• Briefly summarize the background, purpose, results and conclusions of the study, in that order, without headings
• Do not include nonstandard abbreviations, acknowledgments of support, or refer to footnotes or references
• Write with a general scientific audience in mind
• Brand names may not be used in the abstract

F. Introduction

Begin with a brief introductory statement that places the work to follow in historical perspective and explains its intent and significance.

G. Results and Discussion

Briefly present the experimental data in text, tables or figures (for details, see items N and O below). The Discussion should focus on the interpretation and significance of the findings with concise objective comments that describe their relation to other work in the area. Do not repeat information in Results. Results and Discussion may be presented separately or combined into a single section.

H. Materials and Methods

Readers should be able to reproduce the experiments from the information in the methods section, figure legends, table footnotes, and references. Provide the manufacturer's name and location (city, state if within the US; city, country if outside the US) for materials purchased. This would normally include access to the identity (chemical formula) of all reagents employed. Manuscripts must include a statement that all human and animal studies have been approved by the authors' Institutional Review Board, and, for human studies, *JID* requires a statement confirming the Declaration of Helsinki protocols were followed and that patients gave their written, informed consent. See the Editorial Policies for details.

I. Clinical Trials

Reports of clinical trials must conform to the Editorial Policies concerning the registration and reporting of clinical trials. Submissions that do not comply with these specifications will be returned to the authors for correction prior to review.
J. Conflict of Interest

Financial or personal involvements that pose a potential duality of interest for authors should be clearly disclosed under a separate heading entitled 'Conflict of Interest.' If no conflicts exist, please use the standard phrase, "The authors state no conflict of interest." Prior to submission, all authors must complete and sign the Conflict of Interest Disclosure Form. Each author must indicate on this form whether they have financial, equity, patenting or other relevant relationships or arrangements with a product or sponsor of research that might constitute a conflict of interest. More information on conflict of interest can be found on the form and in The Uniform Requirements for Manuscripts Submitted to Biomedical Journals, by the International Committee of Medical Journal Editors.

K. Acknowledgments

A note of acknowledgment is appropriate recognition for contributors who may not be listed as authors. For details on authorship, see JID Editorial Policies. Conflicts of interest should not be listed here; please list these under the 'Conflict of Interest' heading.

L. References

References should be listed alphabetically on a separate page at the end of the manuscript. To save space, the citation of appropriate recent review articles is encouraged. Only published articles and abstracts, and manuscripts in press should be cited in the references. References for abstracts should be followed by the designation "(abstr.)". In the reference list, references with three or fewer authors should list all names; for more than three authors, list the first three names followed by "et al". Abbreviations of journal names must conform to those adopted by Index Medicus. The names of unlisted journals should be spelled out. Show inclusive page numbers. For papers in press, give the title of the publication and the journal name. If the article is published online-only, or online ahead of print, provide the digital object identifier (doi). Unpublished citations such as theses, "personal communications", "in preparation", etc. should be given as a footnote to the text, and must be approved in writing by the individuals cited. Refer to publications in the text as "(Schmidt and Jones, 2000)" or as "(Schmidt et al, 2000)" in the case of three or more authors. Authors should use the latest version of Reference Manager or Endnote for JID reference style.

Example references:

Journal article:

Advance online publication of a journal article:
Author(s). Article title. Journal Title advance online publication, day month year (DOI)
Book chapter:

Entire book:

Abstract:

Website (in the text only):
A partial search of EH sequences from the Phytome database (http://www.phytome.org/, accessed 10 July 2007) showed that...

M. Footnotes

Any citations to unpublished works must be shown as footnotes to the text, not in the reference list. Footnotes should be included in parentheses in the text.

N. Tables

Tabular presentations should be self-explanatory and not duplicate content in the text. Tables should be presented at the end of the manuscript (one table per page), numbered sequentially (1, 2, 3) and cited in chronological order in the text. The table should include an informative title. Do not provide a table legend, but supply information such as the description of the experiment, definition of columns or abbreviations, etc. in footnotes to the title and table contents. Label footnotes 1, 2, 3, etc. Define errors in the table by a footnote, e.g., "mean +/- SD" or "mean +/- SEM". Authors should ensure that the data in the tables are consistent with those cited in the relevant papers in the text, totals add up correctly, and percentages have been calculated correctly.

O. Figures

Figures should be intelligible without reference to the text and should complement the text. Figures should be labeled sequentially (1, 2, 3) and cited in the text, but not embedded within the text. Figures should be submitted as separate files.
Artwork guidelines.

Detailed guidelines for submitting artwork for publication can be found by downloading the artwork guidelines. Please submit production quality artwork with your initial submission. Following peer review, if your paper is accepted for publication, we will not require artwork to be resubmitted if you have followed the guidelines. Please note: file size limitations may require that publication-quality figures be compressed for submission and peer review purposes. Refer to the ScholarOne guidelines for assistance.

Appropriate scientific conduct concerning images.

- No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.

- Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image, and as long as they do not obscure or eliminate any information present in the original.

- The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by arrangement of the figure (i.e., using dividing lines) and in the text of the figure legend.

- If the original data cannot be supplied by the author upon request, the acceptance of the manuscript may be revoked.

- Refer to the article "What's in a picture? The temptation of image manipulation" by Rossner and Yamada (J Cell Biol 166: 11-15, 2004) for details.

Figure sizing.
To avoid size reduction, authors should submit artwork of exact column measurements and crop out unnecessary areas (1 column = 87.50mm; 2 columns = 180mm). Most figures should be presented at 1 column width (or quarter page in size).

**Figure labeling.**

Figure parts should be noted as a, b, c, etc., in a lower case non-serif font. For more on labeling of figures, see the artwork guidelines.

**Figure legends.**

Figure legends should be presented in a separate section of the manuscript. The figure title (a brief, overall description of the figure) should be given in the legend, not on the figure. Legends should explain how an experiment was done and identify parts of the figure (i.e., a, b, c), not interpret the figure. Indicate the meaning of all symbols, keys and abbreviations used in the figure. Error bars should be defined in the legend as "mean +/- SD" or "mean+/-SEM". If you use SEM give n for each point.

**DNA Sequences.**

DNA Sequences must have an EMBL or Genbank database accession number, and this number should be given in the legend to the figure showing the sequence.

**Line drawings.**

Drawings should have clear, uniform lines of thickness. Curves should be smooth. Do not use 3-dimensional graphs unless the third dimension is used for data. Label axes parallel to the axis, not at the top of the graph. Labels must be clearly legible. Use only black and white, not gray, in charts and graphs. The inside of bar graphs should use a patterned black and white print.

**Photomicrographs.**

A scale bar, not magnification, must be placed on micrographs and the scale indicated in the legend, e.g., "scale bar = mm".

**P. Permissions**

If a table or figure has been published or copyrighted, the authors must obtain written permission from the copyright owner to reproduce the material in both print and electronic formats and submit the authorization with the manuscript. This applies to quotes, illustrations and other materials taken from previously published works not in the public domain. The original source should be cited (if reprinting a figure or table, the citation should appear in the figure legend or table footnote).
Q. Abbreviations

Terms used more than five times may be abbreviated and listed with their abbreviations on the title page. Abbreviations not listed in the Standard or Recommended Abbreviations webpage should conform to those listed in *Scientific Style & Format*, 6th ed. (Cambridge University Press, Cambridge, UK, 1994). Capitalize trade names, but use generic names if possible. Trade names may not be used in the title or abstract. The trivial names of chemicals may be used if the formal chemical name is given with the first use of the trivial name.

R. Deposition of Microarray Data

Authors submitting manuscripts containing microarray data may be asked to supply these data as supplementary information at the request of the reviewers. At the time of submission, the microarray data should be presented in a MIAME-compliant standard format. Before publication, the microarray data must be deposited in an approved database and an accession number provided for inclusion in the published paper. Approved databases include Gene Expression Omnibus and ArrayExpress.

S. Supplemental Data

At the Editor's discretion, large tables, data sets, etc. of accepted manuscripts may be published as supplemental data on the *JID* website. The charge for publishing supplemental data is $125 for the first file and $75 per file thereafter. Authors will be charged once the paper is accepted and in the proofing stage.

**What is Supplemental data?**

Supplemental data is peer-reviewed material directly relevant to the conclusion of an article that cannot be included in the printed version owing to space or format constraints. It is posted on the journal's web site and linked to the article when the article is published and may consist of data files, graphics, movies or extensive tables. The printed article must be complete and self-explanatory without the supplementary information. Supplemental data enhances a reader's understanding of the paper but is not essential to that understanding.

Supplemental data must be supplied to the editorial office in its final form for peer review. Supplemental data should be cited in the text as "Figure S1, S2, etc.," "Table S1, S2, etc." or "Supplementary Materials and Methods, etc."

**Guidelines for preparing supplemental information**

All figures, tables and text should be compiled into a single .pdf. Provide titles for each component and include captions or legends under each figure or table. Exceptions to this include Excel files, videos, audios and any other items that cannot be reduced to a flat file format. Please check the final version carefully, as supplementary information cannot be modified by authors after acceptance. Supplementary information is not copyedited by the journal, so ensure that it is
clearly and succinctly presented, and that the terminology conforms to the rest of the report. Publication may be delayed if these guidelines are not followed.

Top of page

**English Language Editing**

Authors who are not native speakers of English may receive criticism from referees or editors about English-language usage in their manuscripts. Difficult language use may distract readers from the science being communicated and may lead to less favorable reviews. To reduce the likelihood of this possibility, we encourage authors to have manuscripts reviewed for clarity by colleagues whose native language is English. When this is not possible, authors may wish to use an editing service such as one of those listed below. The use of such services is at the authors' expense and does not guarantee that articles will be accepted. While the services listed below have been vetted, other commercial editing services may be employed instead. *JID* cannot accept responsibility for the interaction between authors and service providers or for the quality of the work performed.

- American Journal Experts
- BioScience Writers
- Inter-Biotec

Inter-Biotec also provides a free online writing course for researchers whose first language is not English, to help them write for and publish papers in English-language journals.

- SPI Professional Editing Services
- Write Science Right

Top of page

**Publication Charges**

*JID* does not make the payment of page charges a condition for acceptance of a manuscript for publication. As of January 1, 2013, authors will be assessed $150 per printed page, and there will be no additional fees for color reproduction. In extraordinary cases, upon appeal by the author before submission of the article, the Editor may waive the assessment. Supplemental data files are charged at $125 for the first file and $75 per file thereafter.

Top of page

**Accepted Article Preview (AAP)**

To enable readers to access the latest research as soon as possible following acceptance for publication, *JID* has instituted "Accepted Article Preview" (AAP). For all Original Articles and Letters to the Editor accepted after January 1, 2013, we will publish an AAP version within four days of receipt of all final publication materials. The AAP is a .pdf of an accepted article’s text and figures, and it includes a covering page with a disclaimer, along with a watermark and
headers and footers that identify the article as AAP — an unedited version of a peer-reviewed manuscript that has been accepted for publication. The AAP version of the article will be removed once the copyedited, typeset, and proofed version is published online as part of our Advance Online Publication. Both versions will bear the same digital object identifier (DOI), so that articles may be referenced as soon as they appear in the AAP form on the JID website and to ensure that references to the material will be consistent.

The article is only embargoed until the AAP version is published online. In general, this will be 2-4 business days following export of the draft version of the article to the publisher (Nature Publishing Group), although this may vary. Authors will be informed by email on the day their draft is exported.

Advance Online Publication

All original articles and letters to the editor are published ahead of print on Advance Online Publication. This is the final version of the manuscript that will subsequently appear, unchanged, in print.

Proofs

An e-mail will be sent to the corresponding author with a URL link from which proofs can be collected. Proofs must be returned by fax within 48 hours of receipt. Failure to do so may result in a delay to publication. Extensive corrections cannot be made at this stage.

Offprints

Offprints may be ordered using the form accompanying the proof.